All relevant data are within the paper and its Supporting Information files. The nucleotide sequence of PamA from N. meningitidis strain HT1125 has been deposited in the DNA Data Bank of Japan (DDBJ) (accession code: LC511747).

Introduction {#sec001}
============

*Neisseria meningitidis* is a fastidious Gram-negative microorganism that generally exists in the non-invasive so-called "carrier state" at a rate of 0.4--25% in human populations \[[@pone.0237883.ref001], [@pone.0237883.ref002]\]. However, *N*. *meningitidis* exhibits the abilities to cross the epithelial layer of the upper respiratory tract, infiltrate the bloodstream, evade the defenses of the human immune system, adhere to the endothelial layers of peripheral and brain vessels, cross the brain-blood barrier, and replicate in cerebrospinal fluid \[[@pone.0237883.ref003]\]. Although epidemiological analyses previously suggested that a human genetic polymorphism \[[@pone.0237883.ref004]\] and climate conditions \[[@pone.0237883.ref005]\] are important for predicting the outcomes of infection, the reasons why invasive meningococcal diseases (IMD) occur in some individuals, but not in others remain unclear \[[@pone.0237883.ref006]\].

Classical analyses revealed the factors exposed on meningococcal surfaces, such as the polysaccharide capsule, pili, Opa, and Opc, (reviewed in \[[@pone.0237883.ref007]--[@pone.0237883.ref009]\]), and genome mining with whole-genome sequencing (WGS) identified the following meningococcal pathogenic factors: NhhA, NadA \[[@pone.0237883.ref010]\], App \[[@pone.0237883.ref011]\], NalP \[[@pone.0237883.ref012]\], MspA \[[@pone.0237883.ref013]\], TspA \[[@pone.0237883.ref014]\], adhesion complex protein (ACP) \[[@pone.0237883.ref015]\], and fHbp \[[@pone.0237883.ref016]\]. Among the factors described above, meningococcal pili, which are mainly composed of the major pilin, PilE, and three minor pilins, PilV, PilX, and ComP, play the most important roles in the meningococcal infection processes involved in interactions with human epithelial and endothelial cells (reviewed in \[[@pone.0237883.ref017], [@pone.0237883.ref018]\]). To elucidate the molecular mechanisms underlying meningococcal pathogenesis in more detail, functional genomics by linking genotypes to phenotypes have allowed investigation of the relationships between gene transcript abundance or deficiencies and the capacity to function under various physiological conditions to be investigated, by genome-wide signature-tagged mutagenesis (STM) with an infant rat infection model \[[@pone.0237883.ref019]\], with human cultured cells \[[@pone.0237883.ref020]\], and in different media \[[@pone.0237883.ref021]\], microarrays with infection in human cultured cells \[[@pone.0237883.ref022]\], comparative genomics \[[@pone.0237883.ref023], [@pone.0237883.ref024]\], transcriptomics \[[@pone.0237883.ref025]--[@pone.0237883.ref028]\], and proteomics \[[@pone.0237883.ref029]--[@pone.0237883.ref031]\]. However, the mechanisms by which *N*. *meningitidis* causes septicemia and meningitis in humans cannot be completely explained by these characterized factors \[[@pone.0237883.ref032]\].

Although progressive WGS recently identified many genes in the meningococcal genome, more than half of those in the annotated open reading frame have remained as function-unknown hypothetical proteins. One of the difficulties associated with the characterization of meningococcal hypothetical proteins may be the limited number of analytical methods applicable to *N*. *meningitidis*, including tools to directly manipulate meningococcal components \[[@pone.0237883.ref033], [@pone.0237883.ref034]\]. Under these conditions, we also conducted STM to identify the factors responsible in the sequence type (ST)-2032 *N*. *meningitidis* strain, known for its high infectious ability in human brain microvascular endothelial cells (HBMEC) \[[@pone.0237883.ref035]\]. Among the STM mutants with highly defective infectious abilities in HBMEC, we identified PilV \[[@pone.0237883.ref036]\] of the meningococcal pilus and GltT-GltM glutamate transporter \[[@pone.0237883.ref037], [@pone.0237883.ref038]\] as meningococcal pathogenic factors for infection in host cells. However, several STM mutants were identified as disruptants of hypothetical genes, and we noted that, one disruptant of a hypothetical gene annotated as NMB1345 in the *N*. *meningitidis* MC58 genome \[[@pone.0237883.ref039]\], exhibited largely defective internalization ability into HBMEC. However, the deduced amino acid sequence of NMB1345 lacked homology with any function-known proteins from other species. We previously attempted to examine protein-protein interactions using already existing methods, such as the two-hybrid system or a pull-down assay, to find some clues about the function of the NMB1345 protein but were unsuccessful. Therefore, more powerful strategies are needed to elucidate the function of the NMB1345 protein in *N*. *meningitidis*.

One of the appropriate methods for our study is genetic code expansion with non-canonical amino acids (ncAAs) utilizing a pyrrolysyl-tRNA synthetase/tRNA^Pyl^ pair from *Methanosarcina mazei* (MmPylRS/T) \[[@pone.0237883.ref040]\]. The genetic code expansion allows ncAAs containing fluorophores, photocaged groups, photocrosslinkers, metal ion-chelating groups, and other groups to be site-specifically incorporated into target proteins *in vivo* in a broad range of species from *Escherichia coli* to eukaryotic systems, such as *Caenorhabditis elegan*s, fruit flies, and mice (reviewed in \[[@pone.0237883.ref041]\]), thereby enabling *in vivo* examinations of biological functions. Protein photocrosslinking via the incorporation of photoreactive ncAAs has emerged as a superior strategy for identifying physiological interaction partner(s) and their functions \[[@pone.0237883.ref042], [@pone.0237883.ref043]\], and in combination with mass spectrometry (MS), these approaches have resolved biological issues that are difficult or impossible to address using the majority of currently available methods \[[@pone.0237883.ref042]\]. However, the question of whether the orthogonality of the tRNA^Pyl^-PylRS pair is specific or compatible with the translational system in *N*. *meningitidis* has not been addressed.

In the present study, we applied genetic code expansion to *N*. *meningitidis* and developed a method for the genetic incorporation of photoreactive ncAAs into *N*. *meningitidis* in order to identify the physiological function of the NMB1345 protein. After establishing this method, we performed site-specific incorporation with one of the most widely used photoreactive amino acids, *p*-benzoyl-L-phenylalanine (*p*BPa) \[[@pone.0237883.ref044]\], into the NMB1345 protein in *N*. *meningitidis*. By using crosslinking in *N*. *meningitidis* followed by purification and MS analyses of endogenous proteins crosslinked to the NMB1345 protein, we found that the NMB1345 protein specifically interacted with PilE, a major component of meningococcal pili, and thus designated NMB1345 as [P]{.ul}ilE [a]{.ul}ssociated [m]{.ul}olecule [A]{.ul} (PamA) in the present study. We further identified the amino acid residue of PilE crosslinked to PamA K273 and further found that the site-directed PilE mutation reduced both the interaction with PamA and the ability to internalize into HBMEC. Considering these results, we speculated that PamA plays an important role in the formation of meningococcal pili. This is the first study to successfully incorporate ncAAs into *N*. *meningitidis* in order to determine the physiological function of a protein with an unknown function and structure in pathogenic bacteria.

Materials and methods {#sec002}
=====================

Bacterial growth conditions {#sec003}
---------------------------

*N*. *meningitidis* strains HT1125 \[[@pone.0237883.ref035]\] and its derivatives, H44/76 \[[@pone.0237883.ref045]\] as well as derivatives harboring IncQ plasmids ([Table 1](#pone.0237883.t001){ref-type="table"}) were routinely grown on GC agar plates at 37 ^o^C in a 5% CO~2~ atmosphere \[[@pone.0237883.ref046]\]. *E*. *coli* strains were grown in Luria-Bertani (LB) broth liquid cultures (Becton- Dickinson) or on LB plate (LB liquid medium containing 1.5% agar) or in MagicMedia (Invitrogen) at the indicated temperatures. When required, antibiotics were added at the following concentrations: kanamycin at 150 μg/ml, chloramphenicol at 5 μg/ml, erythromycin at 4 μg/ml, and spectinomycin at 75 μg/ml for *N*. *meningitidis*; kanamycin at 50 μg/ml, chloramphenicol at 25 μg/ml, and ampicillin at 50 μg/ml for *E*. *coli*. The *N*. *meningitidis* and *E*. *coli* strains used in the present study are listed in [Table 2](#pone.0237883.t002){ref-type="table"}.

10.1371/journal.pone.0237883.t001

###### IncQ plasmids introduced into *N*. *meningitidis* strains which results were shown in this study.

![](pone.0237883.t001){#pone.0237883.t001g}

  Plasmid   Relative properties                                                                                                         Antibiotic selection marker   References
  --------- --------------------------------------------------------------------------------------------------------------------------- ----------------------------- ----------------------------
  pHT128    Derivative of pGSS33, an IncQ broad-host -range vector                                                                      Tet, Cml                      \[[@pone.0237883.ref033]\]
  pHT1212   Derivative of pHT128 carrying a *lacI*^*q*^-*P*~*tac*~-*MmPylRS\[Y306A/Y384F\]* and two *P*~*lpp*~*-tRNA*^*pyl*^ genes      Tet, Cml                      This study
  pHT1262   Derivative of pHT128 carrying a *lacI*^*q*^*-MmPylRS(\[A302T/N346T/C348T/W417C\])* and two *P*~*lpp*~*-tRNA*^*pyl*^ genes   Tet, Cml                      This study
  pHT936    Derivative of pHT128 carrying *lacI*^*q*^*-P*~*tac*~*-gst*^+^ genes                                                         Cml                           This study
  pHT1355   Derivative of pHT1212 carrying a *P*~*tac*~*-gst E51amb* gene                                                               Cml                           This study
  pHT1356   Derivative of pHT1212 carrying a *P*~*tac*~*-gst F52amb* gene                                                               Cml                           This study
  pHT1357   Derivative of pHT1262 carrying a *P*~*tac*~*-gst E51amb* gene                                                               Cml                           This study
  pHT1358   Derivative of pHT1262 carrying a *P*~*tac*~*-gst F52amb* gene                                                               Cml                           This study
  pHT1263   Derivative of pHT1262 carrying a *pamA*^*+*^*-His*~*6*~ gene                                                                Cml                           This study
  pHT1270   Derivative of pHT1262 carrying a *pamA K208amb-His*~*6*~ gene                                                               Cml                           This study
  pHT1274   Derivative of pHT1262 carrying a *pamA K278amb-His*~*6*~ gene                                                               Cml                           This study
  pHT1276   Derivative of pHT1262 carrying a *pamA K309amb-His*~*6*~ gene                                                               Cml                           This study
  pHT1279   Derivative of pHT1262 carrying a *pamA K341amb-His*~*6*~ gene                                                               Cml                           This study
  pHT1282   Derivative of pHT1262 carrying a *pamA K382amb-His*~*6*~ gene                                                               Cml                           This study
  pHT1284   Derivative of pHT1262 carrying a *pamA K395amb-His*~*6*~ gene                                                               Cml                           This study
  pHT1388   Derivative of pHT1262 carrying a *pamA K278amb-StrepTag*~*2*~*-His*~*6*~ gene                                               Cml                           This study

Tet and Cml stand for tetracycline and chloramphenicol resistance marker, respectively.

10.1371/journal.pone.0237883.t002

###### Strains used in this study.

![](pone.0237883.t002){#pone.0237883.t002g}

  ----------------------------- --------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ----------------------------
  *N*. *meningitidis* strains                                                                                                                                                                  
  **HT1125**                                                                                                                                                                                   
  Strain                        Genotype                                                                                                                          Parent strain                Reference
  HT1125                        *ΔsiaB-ΔsiaD*::*kan* (ST-2032)                                                                                                    \[[@pone.0237883.ref035]\]   
  HT1572                        *ΔsiaB-ΔsiaD*::*kan pamA*::*Tn-spc*                                                                                               HT1125                       This study
  HT1736                        *ΔsiaB-ΔsiaD*::*kan pamA*::*Tn-spc ggt*::*pamA*^*+*^*-cat*                                                                        HT1572                       This study
  HT1822                        *ΔsiaB-ΔsiaD*::*kan ΔpamA*::*spc*                                                                                                 HT1125                       This study
  HT2224                        *ΔsiaB-ΔsiaD*::*kan ΔpamA*::*spc ggt*::*pamA*^*+*^*-cat*                                                                          HT1822                       This study
  HT2215                        *ΔsiaB-ΔsiaD*::*kan pamA'-lacZ-ermC*                                                                                              HT1822                       This study
  HT2217                        *ΔsiaB-ΔsiaD*::*kan pamA'-phoA-ermC*                                                                                              HT1822                       This study
  HT1744                        *ΔsiaB-ΔsiaD*::*kan pilE*^*+*^*-cat* (translational fusion)                                                                       HT1125                       This study
  HT2167                        *ΔsiaB-ΔsiaD*::*kan pilE I12A-cat* (translational fusion)                                                                         HT1125                       This study
  HT2218                        *ΔsiaB-ΔsiaD*::*kan pilF*^*+*^*-FLAG-ermC*                                                                                        HT1125                       This study
  HT2219                        *ΔsiaB-ΔsiaD*::*kan pilF*^*+*^*-FLAG -ermCΔpamA*::*spc*                                                                           HT1822                       This study
  HT2136                        *ΔsiaB-ΔsiaD*::*kan pilP*^*+*^*-FLAG -ermC*                                                                                       HT1125                       This study
  HT2137                        *ΔsiaB-ΔsiaD*::*kan pilP*^*+*^*-FALG-ermCΔpamA*::*spc*                                                                            HT1822                       This study
  HT2132                        *ΔsiaB-ΔsiaD*::*kan pilM*^*+*^*-HA -ermC*                                                                                         HT1125                       This study
  HT2133                        *ΔsiaB-ΔsiaD*::*kan pilM*^*+*^*-HA -ermC ΔpamA*::*spc*                                                                            HT1822                       This study
  HT2211                        *ΔsiaB-ΔsiaD*::*kan pilX*^*+*^*-FLAG-ermC*                                                                                        HT1125                       This study
  HT2212                        *ΔsiaB-ΔsiaD*::*kan pilX*^*+*^*-FLAG -ermC ΔpamA*::*spc*                                                                          HT1822                       This study
  HT1688                        *ΔsiaB-ΔsiaD*::*kan pilE*::*ermC*                                                                                                 HT1125                       \[[@pone.0237883.ref036]\]
  HT1822                        *ΔsiaB-ΔsiaD*::*kan ΔpilV*::*ermC*                                                                                                HT1125                       \[[@pone.0237883.ref036]\]
  HT2230                        *ΔsiaB-ΔsiaD*::*kan pilE*^*+*^*-cat pilX*^*+*^*-FLAG-ermC*                                                                        HT1744                       This study
  HT2231                        *ΔsiaB-ΔsiaD*::*kan pilE I12A-cat pilX*^*+*^*-FLAG-ermC*                                                                          HT2167                       This study
  **H44/76**                                                                                                                                                                                   
  Strain                        Genotype                                                                                                                          Parent strain                Reference
  H44/76                        wild type strain (ST-32, Serogroup B)                                                                                                                          \[[@pone.0237883.ref033]\]
  HT1001                        H44/76 *gyrA* (Nal^R^)                                                                                                            H44/76                       This study
  HT1940                        *ΔpamA*::*spc*                                                                                                                    H44/76                       This study
  HT2095                        *ΔpamA*::*spc pilE*^*+*^*-FLAG-ermC*                                                                                              HT1940                       This stud
  HT2014                        *ΔpamA*::*spc pilE*::*ermC*                                                                                                       HT1940                       This study
  HT2162                        *ΔpamA*::*spc pilE*^*+*^*-ermC* (translational fusion)                                                                            HT1940                       This study
  HT2166                        *ΔpamA*::*spc pilE I12A-ermC* (translational fusion)                                                                              HT1940                       This study
  HT1015                        *pilE*::*ermC*                                                                                                                    H44/76                       \[[@pone.0237883.ref035]\]
  *Escherichia coli* strains                                                                                                                                                                   
  Strain                        Genotype                                                                                                                          References                   
  JM109                         *endA1 gyrA96 hsdR17(rk*^*-*^*mk*^*+*^*) mcrB*^*+*^ *recA1 relA1 supE44 thi-1Δ(lac-proAB) F\'\[traD36 proAB lacI*^*q*^*ZΔM15\]*   Nippon gene                  
  BL21                          F--*dcm ompT hsdSB*(*r*B--*m*B--) *gal*                                                                                           NEB                          
  BL21(DE3)                     F--*dcm ompT hsdSB*(*r*B--*m*B--) *gal λ*(DE3)                                                                                    NEB                          
  ----------------------------- --------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ----------------------------

Production of anti-PamA protein rabbit antiserum {#sec004}
------------------------------------------------

All PCR experiments were performed with PrimeSTAR Max GXL DNA polymerase (Takara Bio, Japan). The approximately 3.5-kb PCR fragment containing the *pamA* gene amplified from *N*. *meningitidis* HT1125 genomic DNA with the primer set (NMB1345-21 and NMB1345-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) was cloned into the pTWV228 vector (Takara Bio, Japan), resulting in pHT922 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}), which is the ancestral plasmid in the present study. A *ΔN-pamA* gene, in which the N-terminal hydrophobic region consisting of the first 23 amino acids was removed ([S1 Fig](#pone.0237883.s001){ref-type="supplementary-material"}), was amplified by PCR with the primer set (NMB1345(pET303)-1(NsiI) and NMB1345(pET303)-2(BH)) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and cloned into the same site of the pET303/CT-His expression plasmid (Invitrogen) to construct pHT934 ([S3 Table](#pone.0237883.s016){ref-type="supplementary-material"}). Regarding the production of the ΔN-PamA protein for rabbit immunization, a 1 L culture of *E*. *coli* strain BL21 (NEB) harboring the plasmid was grown in MagicMedia at 37°C overnight, and the cells were collected. The subsequent purification of the recombinant protein and generation of polyclonal rabbit antibodies to the putative hydrophilic domain of the PamA protein were performed as described previously \[[@pone.0237883.ref046]\].

Construction of meningococcal mutants {#sec005}
-------------------------------------

In order to construct the *N*. *meningitidis pamA* deletion mutant, the 6.3-kb PCR fragment was amplified with the primers (NMB1345-3 and NMB1345-4) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT922, in which a 1.5-kb DNA fragment containing the coding region of the *pamA* gene was completely removed, and ligated with a spectinomycin-resistance gene (*spc)* after phosphorylation to construct pHT930. A 3-kb DNA fragment, in which the *pamA* structural gene was replaced with the *spc* gene, was amplified with the primers (NMB1345-21 and NMB1345-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT930 and transformed into *N*. *meningitidis* strain HT1125, and spectinomycin-resistant (Spc^R^) clones were selected, resulting in the *ΔpamA* mutant HT1822 ([Table 2](#pone.0237883.t002){ref-type="table"}).

The *ΔpamA* mutant complemented with the *pamA*^*+*^ gene at the *ggt* allele was constructed as follows: A chloramphenicol-resistance gene (*cat*) was inserted into the SmaI site downstream of the *pamA* gene of pHT922 to generate pHT923 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}). A 4.6-kb PCR fragment containing the *pamA*^*+*^*-cat* gene was amplified from pHT923, in which the meningococcal *ggt* structural gene was cloned in pTWV228 with primers (M13-RV-ggt-5′and M13-47-ggt-3′) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and cloned into the BstXI site of pHT195 (at the middle of the *ggt* coding region) by In-Fusion cloning (Clontech), resulting in the plasmid pHT924. A 6.3-kb DNA fragment containing the *ggt*::*pamA*^*+*^*-cat* genes was amplified from pHT924 with primers (ggt-3 and ggt-4) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}), transformed into *N*. *meningitidis ggt*::*pamA*^*+*^*-cat* mutants, and chloramphenicol-resistant (Cml^r^) clones were selected, resulting in the *pamA* deletion mutant HT2224, which were ectopically complemented with the *pamA*^*+*^ genes expressed from their own promoter at the *ggt* allele ([Table 1](#pone.0237883.t001){ref-type="table"}).

Since we have demonstrated that the *pilE-cat* translational fusion could work as well as the wild-type *PilE*^*+*^ *N*. *meningitidis* strain \[[@pone.0237883.ref036]\], an *N*. *meningitidis* I12A *pilE* mutant, in which Ile at position 12 was substituted with Ala, was constructed as described previously. In brief, pHT872 (*pilE*^*+*^*-cat* translational fusion on pGEM-3z) ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}) \[[@pone.0237883.ref036]\] was site-directed mutagenized with primers (pilE-I12A-1 and pilE I12A-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) to construct pHT1536 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}). After confirming its sequence, a 1.5-kb PCR fragment containing the *pilE I12A-cat* gene was amplified from pHT1536 by a primer set (T7 and SP6) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and transformed into HT1125. Cml^r^ clones were selected and the mutation was confirmed by direct sequencing as for the *pilE I12A-cat N*. *meningitidis* mutant HT2167 ([Table 1](#pone.0237883.t001){ref-type="table"}).

To construct the *pilE*^*+*^*-ermC* or *pilE I12A-ermC* translational fusion in *N*. *meningitidis* strain H44/76 harboring the IncQ plasmid, a 0.9-kb DNA fragment from HT1125 chromosomal DNA containing the structural gene of the wild-type *pilE* gene and its upstream region was amplified with both primers (pGEM-3z-(SmaI)-2(15mer)-pilE-51 and pilE-52) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}). A 0.2-kb DNA fragment of the *pilE* downstream region was also amplified with a primer set (pilE-53 and pilE-18) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}), and a 0.75-kb DNA fragment of the *ermC* gene containing the SD sequence was amplified from pHT24 with a primer set (ermC-21 and ermC-22) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}). The three PCR fragments were cloned into the SmaI site of pGEM-3z to construct pHT1504 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}). The *N*. *meningitidis* I12A *pilE* mutant was constructed as described above using the primer set (pilE-I12A-1 and pilE I12A-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) with pHT1504 as the template. After the sequence was confirmed, a 1.5-kb PCR fragment containing the *pilE I12A-ermC* genes was amplified from pHT1536 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}) with universal primers (T7 and SP6) and transformed into HT1125. Erm^r^ clones were selected and the mutation was confirmed by direct sequencing as for the *pilE I12A-ermC N*. *meningitidis* mutant HT2166 ([Table 1](#pone.0237883.t001){ref-type="table"}). A 1.5-kb PCR fragment containing the *pilE*^*+*^*-ermC* genes amplified from pHT1504 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}) or the *pilE I12A-ermC* genes amplified from pHT1536 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}) by universal primers (T7 and SP6) was transformed into HT1940. Erm^r^ clones were selected and the mutation was confirmed by direct sequencing as for the *pilE*^*+*^*-ermC* HT2162 or *pilE I12A-ermC* HT2166 *N*. *meningitidis* mutants in the *ΔpamA*::*spc* genetic background ([Table 1](#pone.0237883.t001){ref-type="table"}).

The addition of a FLAG tag to the *pilE* gene at the 3′-terminus on its chromosomal locus was achieved as follows: a 1.6-kb PCR fragment containing the *pilE* allele in H44/76 was amplified with a primer set (pilE-11and pilE-12) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}), and after phosphorylation, it was cloned into pMW119 to construct pHT1419 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}). A 5.8-kb PCR fragment was amplified with a primer set (pilE-17 and FLAG'(15mer)-pilE-18) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT24, and a 1-kb PCR fragment containing the *ermC* gene was also amplified with a primer set (pilE-17'(15mer)-M13-47 and FLAG-RV-M) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT24. The two PCR fragments were ligated by In-Fusion Cloning to construct pHT1420, in which the FLAG tag was fused to the *pilE* structural gene followed by an *ermC* selection marker ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}). A 2.6-kb PCR fragment containing the *pilE*^*+-*^*FLAG-ermC* genes was amplified from pHT1420 with a primer set (pilE-11 and pilE-12) and transformed into HT1940. Erm^r^ clones were selected and the mutation was confirmed by direct sequencing as for the *pilE*^*+*^*-FLAG-ermC N*. *meningitidis* mutant HT2095 ([Table 1](#pone.0237883.t001){ref-type="table"}).

The *pilE* insertional mutant HT2014 was constructed by transforming HT1940 with 500 ng of HT1015 (H44/76 *pilE*::*erm*C) \[[@pone.0237883.ref035]\] chromosomal DNA, followed by the selection of the Erm^r^ strain HT2014 ([Table 1](#pone.0237883.t001){ref-type="table"}).

The addition of a FLAG tag to the *pilF* gene at the 3′-terminus on its chromosomal locus was performed as follows: a 1.8-kb PCR fragment containing the *pilF* allele in the H44/76 *N*. *meningitidis* strain was amplified with a primer set (pMW(SmaI)-up(15mer)-pilF-1 and pMW(SmaI)-down(15mer)-pilF-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and cloned into the SmaI site of pMW119 by In-Fusion cloning to construct pHT1449 ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}). A 6-kb PCR fragment amplified with a primer set (pilF-3 and FLAG'(15mer)-pilF-4) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT1499 and a 1-kb PCR fragment containing the *ermC* gene amplified with a primer set (pilF-3'(15mer)-M13-47 and FLAG-RV-M) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT24 were ligated by In-Fusion Cloning to construct pHT1457, in which the FLAG tag was fused to the *pilF* structural gene followed by an *ermC* selection marker ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}). A 2.8-kb PCR fragment containing the *pilF*^*+*^*-FLAG-ermC* genes was amplified from pHT1457 with a primer set (pMW(SmaI)-up(15mer)-pilF-1 and pMW(SmaI)-down(15mer)-pilF-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}), and then transformed into HT1125 and HT1822. Erm^r^ clones were selected and the mutation was confirmed by direct sequencing as for the *pilF*^*+*^*-FLAG-ermC N*. *meningitidis* mutants HT2218 and HT2219, respectively ([Table 1](#pone.0237883.t001){ref-type="table"}).

A 3.9-kb DNA fragment containing partial *pilM-pilN*^*+*^*-pilO*^*+*^*-pilP*^*+*^ genes in H44/76 *N*. *meningitidis* was amplified with a primer set (pMW(SmaI)-up(15mer)-pilMNOP-3 and pMW(SmaI)-down(15mer)-pilMNOP-4) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and cloned into the SmaI site of pMW119 by In-Fusion cloning to construct pHT1450 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}).

The addition of a FLAG tag to the *pilP* gene at the 3' terminus on its chromosomal locus was achieved as follows: a 7.2-kb DNA fragment amplified with a primer set (pilP-3 and FLAG'(15mer)-pilP-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT1450 and a 1-kb PCR fragment containing the *ermC* gene amplified with a primer set (pilP-3'(15mer)-M13-47 and FLAG-RV-M) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT24 were ligated by In-Fusion cloning to construct pHT1454 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}), in which the FLAG tag was fused to the *pilP* structural gene at the 3' terminus followed by an *ermC* selection marker. A 4.9-kb PCR fragment containing the *pilP*^*+*^*-FLAG-ermC* genes was amplified from pHT1454 with a primer set (pMW(SmaI)-up(15mer)-pilMNOP-3 and pMW(SmaI)-down(15mer)-pilMNOP-4)([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and transformed into HT1125 and HT1822. Erm^r^ clones were selected and the mutation was confirmed by direct sequencing as for the *pilP*^*+*^*-FLAG-ermC N*. *meningitidis* mutants HT2136 and HT2137, respectively ([Table 1](#pone.0237883.t001){ref-type="table"}).

The addition of the HA tag to the *pilM* gene at the 3' terminus on its chromosomal locus was achieved; however, the ORFs of the *pilM* (1.1 kb), *pilN* (0.6 kb), and *pilO* (0.6 kb) genes were very close or overlapped, and thus an *ermC* selection marker was inserted downstream of the *pilO* gene. A 7.1-kb PCR fragment containing the partial *pilM* gene and pMW119 from pHT1450 was amplified with a primer set (pilO-3 and HA'-pilM-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}). A 1.2-kb PCR fragment was amplified with a primer set (HA'(15mer)-pilN-1 and pilO-2) from pHT1450 and a 1-kb *ermC* gene fragment was also amplified with a primer set (pilO-2'(15mer)-M13-RV and pilO-3(15mer)-M13-47) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT24. The three PCR fragments were ligated by In-Fusion Cloning to construct pHT1453, in which the HA tag was fused to the *pilM* structural gene with an *ermC* selection marker ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}). A 2.6-kb PCR fragment containing the *pilM*^*+-*^*HA pilN*^*+*^*pilO*^*+*^*-ermC-pilP* genes was amplified from pHT1453 with a primer set (pMW(SmaI)-up(15mer)-pilMNOP-3 and pMW(SmaI)-down(15mer)-pilMNOP-4) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and transformed into HT1125 and HT1822. Erm^r^ clones were selected and the mutation was confirmed by direct sequencing as for the *pilM*^*+*^*-HA-ermC N*. *meningitidis* mutants HT2132 and HT2133, respectively.

The addition of a FLAG tag to the *pilX* gene at the 3' terminus on its chromosomal locus was achieved as follows: a 0.5-kb *pilX* DNA region containing the 400-bp upstream and 160-bp downstream regions of the *pilX* ochre codon in H44/76 was amplified with a primer set (pMW(SmaI)-up(15mer)-pilX-3 and pMW(SmaI)-down(15mer)-pilX-6) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}), and then cloned into the SmaI site of pMW119 by In-Fusion cloning to construct pHT1594. A 4.7-kb PCR fragment amplified with a primer set (M13-47′(15mer)-pilX-5 and FLAG′(15mer)-pilX-8) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT1594, and a 1-kb PCR fragment containing the *ermC* gene amplified with a primer set (FLAG-RV-M and M13-47) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT24 were ligated by In-Fusion Cloning to construct pHT1597, in which the FLAG tag was fused to the *pilX* structural gene followed by an *ermC* selection marker ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}). A 1.5-kb PCR fragment containing partial *pilX*^*-*^*FLAG-ermC* genes was amplified from pHT1597 with a primer set (pMW(SmaI)-up(15mer)-pilX-3 and pMW(SmaI)-down(15mer)-pilX-6) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and transformed into HT1125 and HT1822. Erm^r^ clones were selected and the mutation was confirmed by direct sequencing as for the *pilX*^*+*^*-FLAG-ermC N*. *meningitidis* mutants HT2211 and HT2212, respectively ([Table 1](#pone.0237883.t001){ref-type="table"}).

*pamA-lacZ* translational fusion *N*. *meningitidis* mutants were constructed as follows: a 3-kb PCR fragment containing the *lacZ* gene was amplified from *E*. *coli* strain W3110 \[[@pone.0237883.ref047]\] chromosomal DNA with the primers (lacZ-21 and M13-RV'(15mer)-lacZ-22) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and a 1-kb *ermC* gene fragment was amplified with universal primers (M13-RV and M13-47) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT24 \[[@pone.0237883.ref033]\]. The two PCR fragments were cloned into a 7.2-kb DNA fragment (designated Fragment C) amplified from pHT922 containing the upstream and downstream regions of the *pamA* gene with the first 408-bp region including the N-terminal membrane spanning region (designated *pamA*′) with a primer set (M13-47′(15mer)-nmb1345-61 and lacZ′-21(15mer)-nmb1345-62) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) by In-Fusion cloning to construct pH1605 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"} and [Fig 2B](#pone.0237883.g002){ref-type="fig"}).

*pamA*′*-phoA* translational fusion *N*. *meningitidis* mutants were constructed as follows: a 1.5-kb PCR fragment containing the *phoA* gene was amplified from *E*. *coli* strain W3110 chromosomal DNA with the primers (phoA-21 and M13-RV'(15mer)-phoA-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}), and a 1-kb *ermC* gene fragment was amplified with universal primers (M13-RV and M13-47) from pHT24 \[[@pone.0237883.ref033]\]. The two PCR fragments were cloned into Fragment C by In-Fusion Cloning to construct pH1603 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}). PCR fragments amplified with nmb1345-5 and nmb1345-21 ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT1605 containing the *pamA*′*-lacZ-ermC*-downstream region of the *pamA* gene or from pHT1603 containing the *pamA*′*-phoA-ermC*-downstream region of the *pamA* gene were transformed to HT1125, and erythromycin-resistant clones were selected, as for the *pamA*′*-lacZ*::*ermC* or *pamA*′*-phoA*::*ermC N*. *meningitidis* mutants on its chromosome HT2215 and HT2217, respectively ([Table 1](#pone.0237883.t001){ref-type="table"} and [Fig 2B](#pone.0237883.g002){ref-type="fig"}).

Assessment of host cell-associated and internalized bacteria {#sec006}
------------------------------------------------------------

The infection of HBMEC with *N*. *meningitidis* was performed as described previously \[[@pone.0237883.ref046]\]. Results are expressed as means ± the standard deviation (SD), and bacterial numbers were statistically compared using the two-tailed Student's *t*-test.

Western blotting {#sec007}
----------------

SDS-PAGE and Western blotting were performed as described previously \[[@pone.0237883.ref048]\].

Observations of meningococci and ezrin accumulation by immunofluorescence staining {#sec008}
----------------------------------------------------------------------------------

HBMEC monolayer preparations, *N*. *meningitidis* infections of these layers, and the preparation of immunostaining samples were performed as described previously \[[@pone.0237883.ref046]\]. Infected HBMEC and attached meningococci were observed using an ECLIPSE E600 microscope (Nikon) with a 100× oil immersion objective.

Construction of IncQ plasmids for *N*. *meningitidis* {#sec009}
-----------------------------------------------------

The mutated *M*. *mazei pylT* (tRNA^Pyl^) and mutated *pylRS* genes for *m*AzZLys (*PylRS*\[Y306A/Y384F\]) \[[@pone.0237883.ref049]\] and *p*BPa (*PylRS* A302T/N346T/C348T/W417C\]) \[[@pone.0237883.ref050]\] (*MmpBpaRS*) were derived from pCDF-Pyl-Fx1 \[[@pone.0237883.ref049]\]. The four point mutations were generated by three-step mutations with the following three primer sets (A302-T and A302-7-R) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}), (N346T-C348T-F and N346-C348-R) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}), and (W417C-F and W417C-R) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) using the Mutagenesis Basal Kit (Takara Bio). The plasmid constructed from pCDF-Pyl-Fx1 as described above was named pCDF-Pyl-Fx3 in this study ([S3 Table](#pone.0237883.s016){ref-type="supplementary-material"}). A 2-kb PCR fragment containing one copy of the *pylRS* gene (Y306A/Y384F) and two copies of the *pylT* genes expressed from the *E*. *coli lpp* promoter \[[@pone.0237883.ref049]\] (*pylRS (Y306A/Y384F)/T)* from pCDF-Pyl-Fx1 or a 2-kb PCR fragment containing one copy of the *MmpBPaRS* genes and two copies of the *pylT* genes expressed from the *E*. *coli lpp* promoter \[[@pone.0237883.ref049]\] (*MmpBPaRS/T*) from pCDF-Pyl-Fx3 were amplified by PCR with a primer set (ptac-12-pylRS-1 and M13-47-reverse-lppT-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}), and then cloned into pTTQ18, an expression vector with a strong *tac* promoter (*P*~*tac*~) controlled by the LacI protein \[[@pone.0237883.ref051]\] using In-Fusion cloning to construct pHT1208 and pHT1261, respectively ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}). The PCR fragment containing the *lacI*^*q*^*-P*~*tac*~*-pylRS\[Y306A/Y384F\]/T* or *lacI*^*q*^*-P*~*tac*~*-MmpBPaRS*/*T* genes was amplified by PCR with primers (M13-47 reverse and ptac-12) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}), and after phosphorylation, the fragment was cloned into the blunted *Sac*I and *Pst*I sites of pHT128, an IncQ plasmid \[[@pone.0237883.ref033]\], resulting in pHT1212 (*lacI*^*q*^*-P*~*tac*~*-pylRS\[Y306A/Y384F\]/T*) and pHT1262 (*lacI*^*q*^*-P*~*tac*~*-MmpBPaRS*/*T)*, respectively ([Table 1](#pone.0237883.t001){ref-type="table"} and [S4 Table](#pone.0237883.s017){ref-type="supplementary-material"}).

PCR fragments containing the *gst* gene derived from pGEX-6P1 (GE Healthcare) with an amber codon at position Glu 51 (*gst E51*) or Phe 52 (*gst F52*) were constructed as follows: the *gst E51* or *gst F52* mutation was introduced by site-directed mutagenesis with two sets of primers (gst E51amb-1 and gst E51amb-2 for *gst E51)* (gst F52amb-1 and gst F52amb-2 for *gst F52)* ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) using the PrimeSTAR Mutagenesis Basal Kit. After the sequence was confirmed, a 0.5-kb PCR fragment containing *Ptac-gstE51amb* or *Ptac-gstF52amb* was amplified with a primer set (tetA-1-gst-up and gst-down-tetA-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and cloned into the SalI site of pHT1212 or pHT1216 to construct pHT1355, pHT1356, pHT1357, and pHT1358, respectively ([Table 1](#pone.0237883.t001){ref-type="table"}).

To construct a series of amber mutations in the *pamA* gene, the His~6~ tag was initially introduced into the 3' terminus of the native *pamA* gene as follows: a 7.2-kb PCR fragment was amplified from pHT922 with a primer set (NMB1345-1 and NMB1345-2-(His)~6~) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}), phosphorylated, and then self-ligated to construct pHT1213 ([Table 1](#pone.0237883.t001){ref-type="table"}).

Amber mutation series (*pamA K-amb*) plasmids (see [S1 Fig](#pone.0237883.s001){ref-type="supplementary-material"}) were constructed by site-directed mutagenesis of pHT1213 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}) with primer sets ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}). The *pamA K-amb* gene on pTWV228 was confirmed by sequencing and the plasmid is listed in [S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}. A 2.2-kb PCR fragment containing the *pamA K-amb* gene was amplified with a primer set (tetA-NMB1345-up and tetA-NMB1345-down) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from the pTWV228-based plasmids listed in [S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}, and cloned into the SalI site of pHT1216 or pHT1262 by In-Fusion cloning to construct IncQ plasmids containing the *lacI*^*q*^*-P*~*tac*~*-pylRS\[Y306A/Y384F\]/T* and *pamA K-amb* genes (pHT1212) or *lacI*^*q*^*-P*~*tac*~*-MmpBPaRS*/*T* and *pamA K-amb* genes (pHT1262) listed in [Table 1](#pone.0237883.t001){ref-type="table"}.

The addition of *StrepTag*~*2*~*-His*~*6*~ synthetic DNA ([S3 Fig](#pone.0237883.s003){ref-type="supplementary-material"}) to the *pamA K278amb* gene was achieved as follows: a 6.5-kb PCR fragment amplified from pHT1242 with a primer set (spacer-1(15mer)-nmb1345-12 and His~6~′(15mer)-nmb1345-11) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) was ligated to *StrepTag*~*2*~*-His*~*6*~ synthetic DNA by In-Fusion cloning to construct pHT1293 ([S2 Table](#pone.0237883.s015){ref-type="supplementary-material"}). A 2.4-kb PCR fragment containing the *pamAK278amb-StrepTag*~*2*~*-His*~*6*~ gene was amplified with a primer set (tetA-NMB1345-up and tetA-NMB1345-down) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from pHT1293 and cloned into the SalI site of pHT1262 by In-Fusion cloning, to construct pHT1388 ([Table 1](#pone.0237883.t001){ref-type="table"}).

The introduction of IncQ plasmids into *N*. *meningitidis* strains was performed as described previously \[[@pone.0237883.ref033]\].

UV crosslinking of whole *N*. *meningitidis* cells expressing the PamA Lys-amber (*pamA K-amb*) mutants by pyrrolysine-based amber suppression with *p*BPa {#sec010}
----------------------------------------------------------------------------------------------------------------------------------------------------------

The *N*. *meningitidis* H44/76 *ΔpamA*::*spc* mutant (HT1940) ([Table 2](#pone.0237883.t002){ref-type="table"}) harboring IncQ plasmids containing *lacI*^*q*^ *-Ptac-MmpBPaRS*/*T* genes and *pamA K-amber* genes ([Table 1](#pone.0237883.t001){ref-type="table"}) was cultivated on GC agar plates containing 1 mM IPTG and 1 mM *p*BPa at 37°C in 5% CO~2~ for 18 hours. To identify the optimal *pamA K-amb* mutants for pyrrolyl-based amber suppression followed by photocrosslinking, *N*. *meningitidis* transformants grown one-fourth of a GC plate were suspended in 50 μl PBS, transferred into the wells of a 96-well plate/strain, and irradiated with 365 nm UV using a FL-365-SD UV lamp stand (Opticode, Japan) at a distance of 2 cm on ice for 2 hours. After harvesting, UV-irradiated bacteria were resuspended in 400 μl of urea buffer (50 mM Tris-HCl pH7.5, 8 M urea, 1% Triton X-100, and 100 mM NaCl) and then transferred into a 1.5-mL tube. Bacteria were disrupted by sonication, and the soluble fraction was obtained by centrifugation. PamA K-amb-His~6~ proteins with expression suppressed by *p*BPa were purified with 200 μL TALON resin (Clontech). The purified fraction (approx. 250 μl) was precipitated by TCA/acetone at -80 ^o^C overnight, and the precipitate was finally dried and suspended in 25 μl 1 × SDS buffer. Aliquots were analyzed by SDS-PAGE.

Identification of endogenous proteins crosslinked with PamA K278(*p*BPa) in *N*. *meningitidis* {#sec011}
-----------------------------------------------------------------------------------------------

To identify endogenous protein(s) crosslinked to PamA K278(*p*BPa) in *N*. *meningitidis*, an synthetic DNA fragment containing twin *Strep*-Tag (StrepTag~2~) \[[@pone.0237883.ref052]\] was further introduced into pHT1274, resulting in pHT1388 ([S3 Fig](#pone.0237883.s003){ref-type="supplementary-material"} and [Table 2](#pone.0237883.t002){ref-type="table"}). *N*. *meningitidis* HT1940 harboring pHT1388 was grown on approximately 200 GC agar plates containing 1 mM IPTG and 1 mM *p*BPa at 37°C in 5% CO~2~ for 18 hours. The bacteria from 3 GC agar plates were suspended in 0.5 mL PBS, transferred into the wells of a 12-well plate (more than 50 wells in total), and irradiated with 365 nm UV on ice for 2 hours. The irradiated bacteria from 2 wells were transferred into a 15-mL tube and harvested by centrifugation. The collected bacteria were suspended in 5 mL IP Lysis buffer (25 mM Tris-HCl pH7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, and 5% glycerol) and disrupted by sonication followed by centrifugation at 12,000 rpm at 4°C for 30 min. The supernatant (soluble fraction) was collected into one tube. Crosslinked proteins were purified by two column chromatography steps using Ni-Sepharose High Performance (GE Healthcare) and *Strep*-Tactin Sepharose (Iba, Germany). The purified fraction was concentrated approximately 70-fold using a VIVASPIN TURBO 15 (MW 50k) Centrifuge Filter unit (Sartorius), to a final volume of approximately 100 μL. An aliquot of the sample was analyzed by 4--12% NuPAGE (Invitrogen), and immunoblotting with an anti-His~6~ monoclonal antibody (mAb) (Wako, Japan). All proteins were also visualized using the CBB staining kit (APRO SCIENCE, Japan) and bands that were also detected by immunoblotting were excised. These bands were subjected to trypsin digestion and peptide extraction. Extracted peptides were dried and resuspended in H~2~O and 0.1% (w/w) trifluoroacetic acid for MS. The LC-MS/MS analysis was performed with an Advance nanoLC (Michrom Biosources) coupled to an LTS Mass Spectrometer (Thermo Fisher Scientific). Proteins were identified by running MASCOT ([http://www.matrixscience.com](http://www.matrixscience.com/)) against the NCBI database (NCBInr 20160202). Candidates with molecular masses that were consistent with the difference between the crosslinked complexes and the PamA protein were selected. The accuracy of each interaction between PamA K278(*p*BPa) and the candidate was further examined by constructing *N*. *meningitidis* HT1940 harboring pHT1388 mutants, in which the FLAG tag was added to the candidate gene on its chromosome, as in the *pilX-FLAG N*. *meningitidis* strain ([Table 1](#pone.0237883.t001){ref-type="table"}) described above.

Identification of the counterpart of the amino acid residue of PilE crosslinked with PamA K278(*p*BPa) {#sec012}
------------------------------------------------------------------------------------------------------

A DNA fragment containing *ΔN-pamA K278amb* was amplified from pHT1242 with a primer set (NMB1345(pGEX)-1(BH) and NMB1345(pGEX)-2(XhoI)) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and cloned into the same sites of pMAL-c2 (NEB) to construct pHT1473 ([S3 Table](#pone.0237883.s016){ref-type="supplementary-material"}). A 0.5-kb PCR fragment containing the Gln~6~-ΔN-PilE gene, in which the first 9 amino acids (PilE leader peptides in *N*. *meningitidis*) were replaced with 6 glutamine residues (Gln~6~) (see the [Results](#sec015){ref-type="sec"} section), was amplified with a primer set ((Gln)~6~-pilE-45 and pCDF-1b(PacI)(15mer)-pilE-44) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) from H44/76 *N*. *meningitidis* chromosomal DNA, and designated as fragment B. To clone the PCR fragment into pCDF-1b-kan ([S3 Table](#pone.0237883.s016){ref-type="supplementary-material"}) \[[@pone.0237883.ref053]\], a 3.6-kb DNA fragment was amplified from pCDF-1b-kan with a primer set (pCDF-1b (downstream of PacI) and (Gln)~6~(15mer)-pCDF-1b-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and ligated to PCR fragment B by In-Fusion Cloning to construct pHT1447 ([S3 Table](#pone.0237883.s016){ref-type="supplementary-material"}), in which the ΔN-(Gln)~6~-PilE protein was expressed from the T7 promoter (P~T7~). A 0.6-kb PCR fragment containing the *P*~*T7*~*- ΔN-(Gln)*~*6*~*-pilE* gene was amplified from pHT1447 with a primer set (pSTV28(SmaI-5′)-pCDF-1b-1 and pSTV28(SmaI-3′)-pCDF-1b-2) ([S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}) and cloned into the SmaI site of pSTV28 (Takara Bio) by In-Fusion Cloning to construct pHT1474 ([S3 Table](#pone.0237883.s016){ref-type="supplementary-material"}). *E*. *coli* BL21(DE3) cells harboring pCDF-Pyl-Fx3, pHT1473, and pHT1474 were cultivated in 100 mL MagicMedia containing 1 mM *p*BPa at 30°C overnight. The harvested bacteria were suspended in 1.25 mL PBS and divided into 5 aliquots (0.25 mL/tube), transferred into the wells of a 24-well plate/aliquot, and irradiated with 365 nm UV light on ice for 2 hours. UV-irradiated bacteria were collected again in one tube and disrupted by suspension in 1 mL B-PER (Thermo) containing protease inhibitor cocktail (Nacalai Tesque, Japan), followed by centrifugation at 12,000 rpm at 4°C for 30 min. The MBP-ΔN-PamA K278(*p*BPa) protein crosslinked to Gln~6~-ΔN-PilE \[as well as uncrosslinked MBP-ΔN-PamA K278(*p*BPa)\] was purified with amylose resin (NEB). The purified fraction was concentrated approximately 70-fold using a VIVASPIN TURBO 15 (MW 50k) Centrifuge Filter unit (Sartorius) to a final volume of approximately 250 μL. An aliquot of the sample was analyzed by 4--12% NuPAGE (Invitrogen), and the bands corresponding to the complex containing MBP-ΔN-PamA K278(*p*BPa) crosslinked to Gln~6~-ΔN-PilE were excised. In addition, an uncrosslinked band corresponding to MBP-ΔN-PamA K278(*p*BPa) was isolated for a comparative analysis. The band corresponding to the Gln~6~-ΔN-PilE protein was also excised. The amino acid residue of Gln~6~-ΔN-PilE crosslinked to ΔN-PamA K278(*p*BPa) was identified by comparing peptides from the three bands as described previously \[[@pone.0237883.ref054]\].

### Transmission Electron Microscopy (TEM) {#sec013}

Negatively stained samples were prepared for TEM as described previously \[[@pone.0237883.ref055]\]. Electron microscopy was performed with a Hitachi H-7600 Transmission Electron Microscope.

Measurement of the ratio of pilus components to PilE in purified pili {#sec014}
---------------------------------------------------------------------

Meningococcal pili were prepared as described previously \[[@pone.0237883.ref036]\]. The relative amounts of PilF-FLAG, PilP-FLAG, PilM-FLAG, PilV, and PilX-FLAG to PilE in purified pili were examined by Western blotting with anti-FLAG mAb (Wako, Japan), anti-PilV \[[@pone.0237883.ref036]\], or anti-PilE rabbit serum \[[@pone.0237883.ref033]\] with appropriate dilutions using a quantification program in Fusion Capt 17 in Fusion Solo 7S (M&S Instruments). Results are expressed as means ± SD. The adhered and internalized bacterial numbers and the relative amounts of pilus components to PilE in purified pili were compared using the two-tailed Student's *t-*test, and *P* values of \<0.05 were considered significant.

Results {#sec015}
=======

Genetic evidence that a hypothetical protein annotated as NMB1345 is important for *N*. *meningitidis* internalization into HBMEC {#sec016}
---------------------------------------------------------------------------------------------------------------------------------

During the course of our research on the infectious abilities of the ST-2032 *N*. *meningitidis* strain mutagenized by STM to HBMEC, we found that a transposon mutant, in which the gene annotated as NMB1345 (renamed as PamA in this study) in the *N*. *meningitidis* MC58 genome \[[@pone.0237883.ref039]\] was disrupted and resulted in defective infectious ability in HBMEC ([Fig 1A](#pone.0237883.g001){ref-type="fig"}). To confirm the relationship between the mutation and infectious defect in the mutant, we constructed a null mutant (HT1822 *ΔpamA*::*spc*) and an ectopically complemented strain with the wild-type *pamA*^*+*^ gene at the *ggt* locus (HT2224) and examined their infectious activities in HBMEC ([Fig 1B](#pone.0237883.g001){ref-type="fig"}). While the insertional and null mutants adhered to HBMEC less efficiently than the wild-type strain HT1125, the number of internalized bacteria largely decreased to approximately 1/100 of HT1125 and the defect in internalized bacterial numbers was recovered in HT2224. These results indicate that the mutation in the *pamA* gene affects meningococcal infection in HBMEC, particularly internalization.

![Characterization of Δ*pamA N*. *meningitidis* mutant.\
(A) Schematic representation of the wild-type, insertion, and deletion mutants in the *pamA* gene and ectopic complementation of the *pamA*^*+*^ gene at the *ggt* locus in *N*. *meningitidis* strains. (B) Effect of *ΔpamA* mutation on *N*. *meningitidis* infection of HBMEC. The adherence (left) and internalization (right) of *pamA N*. *meningitidis* mutants to HBMEC, and the effects of complementation of the *pamA*^*+*^ gene in the *pamA* deletion mutant on bacterial infection. Each value is the mean ± standard error of the mean (CFU per 10^4^ HBMEC) from at least four experiments. Open, filled, light gray, and dark gray bars indicate the bacterial number of *N*. *meningitidis* wild-type *pamA*^*+*^ (HT1125), *pamA*::*Tn-spc* (HT1572), and *ΔpamA*::*spc* (HT1822), and *pamA*^*-*^ mutants in which the *pamA*^*+*^ gene was ectopically complemented (HT1736 and HT2224), respectively (see [S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}). \**P*\<0.01, \#*P*\<0.05, significantly different from the *pamA*^*+*^ strain or *pamA*^*-*^ mutants complemented with the *pamA*^*+*^ gene. (C) Immunofluorescence microscopy showing the accumulation of ezrin beneath *N*. *meningitidis*-infected HBMEC. The HBMEC monolayer was infected with wild-type *pamA*^*+*^ (middle-left), *ΔpamA* (middle-right), and *ΔpamA/pamA*^*+*^ (right) *N*. *meningitidis* strains. A non-infected HBMEC monolayer is also shown in the left panels. Bacteria and HBMEC were observed by phase-contrast microscopy (upper panels). Ezrin was immunostained with an anti-ezrin mAb and Alexa Fluor 488-conjugated rabbit anti-mouse IgG (green channel, lower panels).](pone.0237883.g001){#pone.0237883.g001}

We also investigated host cell cytoskeleton rearrangements caused by meningococcal infection by monitoring the localization of ezrin, because the accumulation of ezrin beneath meningococci on HBMEC is required for bacterial internalization into host cells \[[@pone.0237883.ref036], [@pone.0237883.ref037]\] ([Fig 1C](#pone.0237883.g001){ref-type="fig"}). While ezrin was widely distributed throughout non-infected cells, it was condensed at the site of bacterial attachment in HBMEC infected with wild-type *N*. *meningitidis* strain HT1125. In contrast, ezrin condensation was not observed in cells infected with the *ΔpamA N*. *meningitidis* mutant HT1822, but was detected in HT2224 (*ΔpamA/pamA*^*+*^). These results are consistent with previous findings, and strongly suggest that PamA participates in the meningococcal-elicited bacteria-induced reorganization of the host cell cytoskeleton upon *N*. *meningitidis* infection.

Characterization of the biochemical properties of PamA in *N*. *meningitidis* {#sec017}
-----------------------------------------------------------------------------

The deduced amino acid sequence of the PamA protein consists of 516 residues ([S1 Fig](#pone.0237883.s001){ref-type="supplementary-material"}) with a predicted molecular mass of 57 kDa. The hydrophobicity analysis indicated that the PamA protein had a one membrane-spanning region at its N terminus ([S1 Fig](#pone.0237883.s001){ref-type="supplementary-material"}), suggesting that the PamA protein is localized at the membrane in *N*. *meningitidis*. To clarify the localization in *N*. *meningitidis*, cellular proteins were biochemically fractionated using a differential detergent solubilization method \[[@pone.0237883.ref045]\] and analyzed by Western blotting ([Fig 2A](#pone.0237883.g002){ref-type="fig"}). LptA, a meningococcal inner membrane (IM) protein \[[@pone.0237883.ref055]\], was largely detected in the 4% Triton X-100 soluble (IM-enriched) fraction, supporting the proper fractionation in this experiment. Under the same conditions, the PamA protein was mainly enriched in the IM-rich fraction. This result suggests that PamA is located at the IM in *N*. *meningitidis*.

![Characterization of the biochemical properties of the PamA protein in *N*. *meningitidis*.\
(A) Western blot analyses of subcellular fractions of the PamA protein in *N*. *meningitidis* strain HT1125. A whole-cell lysate periplasmic fraction (P) isolated by CHCl~3~ shock, cytoplasmic and periplasmic fraction (CP), IM-enriched fraction, and outer membrane (OM)-enriched fraction were prepared by the sonication method from the *N*. *meningitidis* strain, as described previously \[[@pone.0237883.ref045]\]. Western blotting with anti-PamA (left) and anti-LptA (right) \[[@pone.0237883.ref055]\] rabbit antisera. LptA is a control for the proper isolation of the IM-rich fraction. Black and gray arrows show PamA and LptA, respectively. (B) Membrane topology of the PamA protein using the *pamA*′*-lacZ* and *pamA*′*-phoA* fused *N*. *meningitidis* strain. The hatched region consists of the 20 amino acid residues corresponding to the putative membrane-spanning region ([S1 Fig](#pone.0237883.s001){ref-type="supplementary-material"}). The first 408-bp region of the *pamA* gene was fused to the *lacZ* or *phoA* gene, and the gene was incorporated into the *pamA* locus on the meningococcal chromosome. (C) β-Galactosidase and alkaline phosphatase activities. (D,E) Western blot of spheroplasted *N*. *meningitidis* strain H44/76 harboring pHT936 (an IncQ plasmid expressing the *gst*^*+*^ gene, [Table 1](#pone.0237883.t001){ref-type="table"}) followed by a treatment with Proteinase K. Aliquots of the sample were analyzed by Western blotting with anti-GST mAb (D) and anti-PamA rabbit serum (E). Black and gray arrows show PamA and GST, respectively.](pone.0237883.g002){#pone.0237883.g002}

We also investigated the membrane topology of the PamA molecule in *N*. *meningitidis* by constructing *N*. *meningitidis* mutants, in which the first N-terminal 136 amino acid residues of PamA including the membrane-spanning region, termed *pamA*′, were fused to the *lacZ* or *phoA* gene \[[@pone.0237883.ref056]\] on the chromosome ([Fig 2B](#pone.0237883.g002){ref-type="fig"})(see [Materials and Methods](#sec002){ref-type="sec"}). While the wild-type HT1125 and *pamA*′*-lacZ N*. *meningitidis* HT2215 strains ([Table 2](#pone.0237883.t002){ref-type="table"}) did not exhibit β-galactosidase activity, the *pamA*′*-phoA N*. *meningitidis* strain HT2217 ([Table 2](#pone.0237883.t002){ref-type="table"}) showed alkaline phosphatase activity ([Fig 2C](#pone.0237883.g002){ref-type="fig"}). Since the alkaline phosphatase activity of PhoA was detected only in the periplasmic space \[[@pone.0237883.ref057]\], these genetic results suggest that the hydrophobic region of the PamA protein faces the periplasmic side. We also biochemically examined the membrane topology, using a Proteinase K digestion experiment with the spheroplasted *N*. *meningitidis* strain expressing glutathione S-transferase (GST) from an IncQ plasmid ([Fig 2D and 2E](#pone.0237883.g002){ref-type="fig"}). Under the condition where the cellular protein GST was mostly protected from Proteinase K digestion ([Fig 2D](#pone.0237883.g002){ref-type="fig"}), PamA was largely digested ([Fig 2E](#pone.0237883.g002){ref-type="fig"}). Collectively, these results suggest that PamA is localized at the IM and faces the periplasmic space in *N*. *meningitidis*.

Incorporation of ncAAs into proteins in living *N*. *meningitidis* {#sec018}
------------------------------------------------------------------

To attempt the application of genetic code expansion to *N*. *meningitidis* for the incorporation of ncAAs with a photocrosslinker into the PamA protein, we used two mutated *MmPylRS/T* genes to genetically encode ncAAs in *N*. *meningitidis*. A previous study reported that a modified *MmPylRS* gene for *E*. *coli*, *MmPylRS*\[Y306A/Y384F\] \[[@pone.0237883.ref049]\] is applicable to *N*^*ε*^-(*m*-azidobenzyloxycarbonyl)-L-lysine (*m*AzZLys) ([Fig 3A](#pone.0237883.g003){ref-type="fig"}, left), which is a photocrosslinker excited by ultraviolet (UV) irradiation \[[@pone.0237883.ref058]\], and *MmPylRS*(\[A302T/N346T/C348T/W417C\]) \[[@pone.0237883.ref050]\] (*MmpBPaRS*) is optimized for *p-*benzoyl-L-phenylalanine (*p*BPa) ([Fig 3A](#pone.0237883.g003){ref-type="fig"}, right), which is also one of the widely used photocrosslinkers \[[@pone.0237883.ref044]\].

![Incorporation of ncAAs into *N*. *meningitidis* proteins monitored by Western blotting.\
(A) Chemical structures of ncAAs, *m*AzZLys (Left) or *p*BPa (right) used in this study. (B) Estimation of the efficiency of pyrrolysine-based amber suppression with *m*AzZLys or *p*BPa for GST E51amb or GST F52amb in *N*. *meningitidis*. Bacterial extracts equivalent to an OD~600~ of 0.1 were analyzed by Western blotting with an anti-GST mAb. The horizontal black arrow shows the full-length GST protein. Numbers indicate relative suppression efficiency when wild-type GST expression is defined as 100%. (C) Detection of irradiation- and time-dependent GST dimerization of GST F52 (*p*BPa) in *N*. *meningitidis*. Bacterial extracts equivalent to an OD~600~ of 0.05, irradiated with UV light for the indicated times, were analyzed by Western blotting with an anti-GST mAb. Dark gray and black arrows show the monomer and dimer forms of the GST protein, respectively. The light gray arrow shows an unspecified form of GST generated by UV irradiation.](pone.0237883.g003){#pone.0237883.g003}

We examined the incorporation of *m*AzZLys and *p*BPa in *N*. *meningitidis* by biochemically monitoring the suppression of the amber codon at position Glu51 or Phe52 of GST (GST E51amb or GST F52amb) by Western blotting ([Fig 3B](#pone.0237883.g003){ref-type="fig"}). The expression of both the *gst E51amb* and *gst F52amb* mutants was suppressed by *p*BPa, while the *gst F52amb* mutant was not suppressed by *m*AzZLys. The suppression efficiency could be considered as approximately 25% of the wild-type GST protein with *p*BPa in the *gst E51amb* mutant, and 37% and 35% with *m*AzZLys and *p*BPa in the *gst F52amb* mutant, respectively. Since the incorporation efficiency of ncAAs is approximately 35--50% in *E*. *coli* \[[@pone.0237883.ref059]\], this result suggested that genetic code expansion by the two modified *MmPylRS/T* genes was efficiently conducted in *N*. *meningitidis* ([Fig 3B](#pone.0237883.g003){ref-type="fig"}). These results obtained by biochemical and genetic pyrrolysine-based amber suppression suggest that *m*AzZLys and *p*BPa are incorporated into the GST protein in *N*. *meningitidis*. The proper incorporation of *p*BPa into a protein in *N*. *meningitidis*, as determined by an MS analysis, was examined with PamA K278 (*p*BPa)(see a later section, [S5 Fig](#pone.0237883.s005){ref-type="supplementary-material"}) since the amounts of GST proteins in *N*. *meningitidis* were too low to purify.

We further examined the UV crosslinking by using whole bacterial cells ([Fig 3C](#pone.0237883.g003){ref-type="fig"}). Longer UV irradiation increased the amount of the dimer form of GST, and the majority of GST F52(*p*BPa) was fixed as the dimer form for 2 hours because GST is a dimeric enzyme \[[@pone.0237883.ref044], [@pone.0237883.ref060], [@pone.0237883.ref061]\]. On the other hand, the dimerization of the GST E51amb(*m*AzZLys) and GST E51(*p*BPa) proteins was not observed by photocrosslinking, while GST E51(*m*TmdZLys) dimerized in *E*. *coli* \[[@pone.0237883.ref062]\], indicating that the processes involved in UV crosslinking with ncAAs do not always function well in *N*. *meningitidis*. Collectively, these results demonstrated that physiological transient protein-protein interactions can be detected by crosslinking via the incorporation of photoreactive ncAAs in *N*. *meningitidi*s and showed that the incorporation of ncAAs by pyrrolysine-based amber suppression could be performed in *N*. *meningitidi*s.

Incorporation of a genetically encoded photocrosslinking amino acid into the PamA protein to identify the accompanying protein in *N*. *meningitidis* {#sec019}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Since it was not possible to predict the three-dimensional structure of PamA by Phyre2 \[[@pone.0237883.ref063]\], due to the lack of homology to any other protein identified to date, we were unable to speculate which amino acid residues are exposed on the outside of the PamA molecule in *N*. *meningitidis*. Therefore, the identities of suitable amino acid residues for the incorporation of photoreactive ncAAs into the PamA protein remained unclear. Thus, in the present study, we focused on the lysine (Lys or K) residue for amber (UAG) substitution because lysine is primarily located on protein surfaces \[[@pone.0237883.ref064], [@pone.0237883.ref065]\]. Forty Lys residues are present in the PamA protein ([S1 Fig](#pone.0237883.s001){ref-type="supplementary-material"}), and we constructed three *pamA* amber mutants (designated as *pamA K-amb*) at K148 (*pamA K148amb*), K273 (*pamA K273amb*), and K388 (*pamA K388amb*) to estimate the proper position(s) in the PamA protein for ncAAs incorporation. *N*. *meningitidis* strain H44/76 *ΔpamA* (HT1940) expressing the *MmPylRS\[Y306A/Y384F\]/T* genes and one of the three *pamA K-amb* genes on an IncQ plasmid was cultivated in the presence of *m*AzZLys, and whole bacterial extracts were analyzed by Western blotting ([S2A Fig](#pone.0237883.s002){ref-type="supplementary-material"}). The full length and a sufficient amount of PamA K148amb by incorporation of *m*AzZLys \[(PamA K148(*m*AzZLys)\], PamA K273(*m*AzZLys), and PamA K388(*m*AzZLys) were only observed in the presence of *m*AzZLys, suggesting that *m*AzZLys is incorporated into the PamA protein by pyrrolysine-based amber suppression in *N*. *meningitidis*. We also examined UV-irradiated whole bacterial cells by Western blotting, faint bands appeared to correspond to proteins crosslinked to PamA (*m*AzZLys), were detected in the PamA K273(*m*AzZLys) and PamA K388(*m*AzZLys) samples ([S2B Fig](#pone.0237883.s002){ref-type="supplementary-material"}). The same result was also obtained for *N*. *meningitidis* strain HT1940 expressing the *MmpBPaRS/T* genes and one of the three *pamA K-amb* genes on an IncQ plasmid, cultivated in the presence of *p*BPa ([S3 Fig](#pone.0237883.s003){ref-type="supplementary-material"}). These results indicate that the Lys residues located from position Lys148 to the carboxy-terminal end ([S1 Fig](#pone.0237883.s001){ref-type="supplementary-material"}) were localized on the surface of the PamA molecule in *N*. *meningitidis*. Moreover, the amber suppression appeared to be more efficiently for PamA K273(*p*BPa) and PamA K388(*p*BPa) with *p*BPa than with *m*AzZLys ([Fig 4](#pone.0237883.g004){ref-type="fig"} and [S3 Fig](#pone.0237883.s003){ref-type="supplementary-material"}). Thus, the photocrosslinking experiments by pyrrolysine-based amber suppression described hereafter were conducted with the *p*BPa and *MmpBPaRS/T* genes.

![PamA K208(*p*BPa), PamA K278(*p*BPa), PamA K314(*p*BPa), PamA K382(*p*BPa) and PamA K395(*p*BPa) proteins crosslinked to unidentified endogenous proteins in *N*. *meningitidis*.\
UV crosslinking of Pam K208amb, K278amb, K309amb, K341amb, K395amb, and K382amb mutants expressed by pyrrolysine-based amber suppression with *p*BPa in *ΔpamA N*. *meningitidis*. Bacteria that grew on one-fourth of a GC agar plate in the presence of 1 mM *p*BPa were crosslinked by UV light irradiation for 2 hours and then the PamA K(*p*BPa)-His~6~ protein was purified. An aliquot was analyzed by anti-His~6~ mAb. The black arrow shows the full-length PamA K-amb protein expressed by pyrrolysine-based amber suppression with *p*BPa, and the gray arrow indicates protein complexes crosslinked between PamA K(*p*BPa) and unidentified endogenous proteins in *N*. *meningitidis*.](pone.0237883.g004){#pone.0237883.g004}

To confirm the proper position(s) for the incorporation of *p*BPa into the PamA protein, we constructed 26 *pamA K-amber* mutants, in which each Lys residue located from position Lys148 to the carboxy-terminal end in the PamA protein was replaced with the amber codon ([S1 Fig](#pone.0237883.s001){ref-type="supplementary-material"}, [Table 1](#pone.0237883.t001){ref-type="table"} and [S4 Table](#pone.0237883.s017){ref-type="supplementary-material"}). UV-irradiated *N*. *meningitidis* strain HT1940 cells expressing the *MmpBPaRS/T* and *pamA K-amber-His*~*6*~ genes were analyzed by Western blotting ([S3 Fig](#pone.0237883.s003){ref-type="supplementary-material"}). Some PamA(*p*BPa) mutants seemed to be crosslinked to some endogenous protein in *N*. *meningitidis* (shown in red in [S3 Fig](#pone.0237883.s003){ref-type="supplementary-material"}), and the more detailed analysis revealed that the following six *pamA K-amber* mutants with expression suppressed by *p*BPa \[K208(*p*BPa), K278(*p*BPa), K309(*p*BPa), K341(*p*BPa), K382(*p*BPa), and K395(*p*BPa)\] appeared to be crosslinked to some endogenous proteins in *N*. *meningitidis* (shown in red in [Fig 4](#pone.0237883.g004){ref-type="fig"}) while K309(*p*BPa) was eliminated. In the present study, we focused only on the proteins crosslinked to PamA K278(*p*BPa), because the three bands with the highest intensities were found in the PamA K278(*p*BPa) sample.

To characterize the 150-, 140-, and 85-kDa protein complexes that contained an endogenous protein crosslinked to PamA K278(*p*BPa), we added a Twin-Strep tag (Strep~2~) \[[@pone.0237883.ref066]\] and His~6~ tag at the carboxy-terminal end ([S4 Fig](#pone.0237883.s004){ref-type="supplementary-material"}) and purified the three corresponding protein complexes from *N*. *meningitidis* strain HT1940 harboring pHT1388 grown on approximately 200 plates as described in the Materials and Methods. During the purification process, we also obtained the purified PamA K278 (*p*BPa) protein expressed in *N*. *meningitidis*. The incorporation of *p*BPa at K278amb of PamA-Strep~2~ -His~6~, was confirmed by MS analyses ([S5 Fig](#pone.0237883.s005){ref-type="supplementary-material"}). This result demonstrates that an ncAA was selectively incorporated into a protein in *N*. *meningitidis*.

The three corresponding protein complexes were subjected to a gel-based proteomic analysis using MS ([Fig 5A and 5B](#pone.0237883.g005){ref-type="fig"}). A compilation of the results obtained using MASCOT (MATRIX SCIENCE, Japan) suggested several candidates, and we selected those with higher scores and numbers of matched peptides for more reliable results in the present study ([Table 3](#pone.0237883.t003){ref-type="table"}). Since the molecular mass of PamA-Strep~2~-His~6~ is approximately 62 kDa due to the addition of Strep~2~-His~6~ at the carboxy-terminal end ([S4 Fig](#pone.0237883.s004){ref-type="supplementary-material"}), the bands corresponding to 150- and 140-kDa were presumed to contain counterparts with a molecular mass of approximately 100 kDa. PamA is listed as the top score of the MASTCOT analysis ([Table 3](#pone.0237883.t003){ref-type="table"}) for the 150 and 140 kDa bands, providing support for the presence of this protein in the two bands. On the other hand, we did not identify any candidate with a deduced molecular mass from 80 to 90 kDa by MASCOT ([Table 3](#pone.0237883.t003){ref-type="table"}). To examine the possibility that the observed molecular mass on SDS-PAGE was different from the calculated molecular mass in the database, we constructed *N*. *meningitidis* mutants that expressed the FLAG-tagged proteins of 5 candidates with estimated molecular masses of 75--160 kDa for 150 kDa, and those of 9 candidates with estimated molecular masses of 48--74 kDa (shown in bold in [Table 3](#pone.0237883.t003){ref-type="table"}). Crosslinked samples from the *N*. *meningitidis* mutants expressing the FLAG-tagged protein, Mm*p*BPaRS/T and PamA K278(*p*BPa)-Strep~2~-His~6~, were examined by Western blotting; however, none of these candidates were crosslinked to PamA K278(*p*BPa) in *N*. *meningitidis*. Considering these results, the two proteins presented by the 150- and 140-kDa bands with the highest intensities on Western blotting apparently correspond to the homo-trimer of the PamA protein (see [Discussion](#sec023){ref-type="sec"} and [S12 Fig](#pone.0237883.s012){ref-type="supplementary-material"}).

![Purification and identification of an endogenous protein crosslinked to PamA K278(*p*BPa)-Strep~2~-His~6~.\
Proteins in each purification step were analyzed by 4--12% SDS-PAGE and staining with the CBB staining kit (A) and Western blotting with anti-His~6~ mAb (B). Lane 1, molecular mass standards; lane 2, *N*. *meningitidis* crude soluble extract; lane 3, after the Ni-Sepharose column; lane 4, after dialysis with IP Lysis buffer; lane 5, after the Strep-Tactin Sepharose column; lane 6, after concentration with VIVASPIN TURBO 15. Black and red arrows indicate K278(*p*BPa)-Strep~2~-His~6~ and the unidentified endogenous proteins crosslinked to PamA K278(*p*BPa)-Strep~2~-His~6~, respectively. (C) The PilE-FLAG protein was crosslinked to PamA K278(*p*BPa) in *N*. *meningitidis*. The black arrow shows the full-length PamA K278amb protein expressed by pyrrolysine-based amber suppression with *p*BPa, and the gray arrow indicates the homotrimer (See text) in *N*. *meningitidis*. The red arrow shows the complex of PilE-FLAG crosslinked to PamA K278(*p*BPa)-Strep~2~-His~6~ in *N*. *meningitidis*. +/- indicates the presence or absence of *p*BPa, and irradiation or no irradiation with UV light, respectively. (D) The crosslinked band was reacted with anti-PilE rabbit serum. Black and gray arrows show PamA K278(*p*BPa)-Strep~2~-His~6~ and the putative homotrimer complex of PamA K278(*p*BPa), respectively, in *N*. *meningitidis*. The red arrow shows the complex of PilE crosslinked with PamA K278(*p*BPa)-Strep~2~-His~6~ in *N*. *meningitidis*. +/- indicates the presence or absence of the *pilE* gene, and irradiation or no irradiation with UV light, respectively.](pone.0237883.g005){#pone.0237883.g005}
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###### Summary of the protein candidates crosslinked to PamA in *N*. *meningitidis* identified by mass spectrometry.

![](pone.0237883.t003){#pone.0237883.t003g}

  -------------------------------------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------- -------------------------------- -------------------------------- ------------------ -----------------------
  1\. Protein identified from the photocrosslinking products for a molecular weight around 150kDa                                                                                                                                                                                       
  **Accession number**                                                                               **Protein name**                                             ***N*. *meningitidis* strain**   **Estimated Molecular weight**   **Number of matched peptides**   **MASCOT score**   **Sequence coverage**
  *gi\|325136153*                                                                                    *hypothetical protein NMBM0579_0886*                         *NMBM0579_0886*                  *57kDa*                          *102*                            *1843*             *25%*
  *gi\|325144519*                                                                                    *hypothetical protein*                                       *NMBM01240013_0931*              *57kDa*                          *99*                             *1758*             *24%*
  *gi\|325140435*                                                                                    *hypothetical protein*                                       *CU385*                          *57kDa*                          *93*                             *1718*             *24%*
  *gi\|488174415*                                                                                    *hypothetical protein*                                                                        *57kDa*                          *93*                             *1920*             *22%*
  **gi\|485353984**                                                                                  **DNA-directed RNA polymerase, β subunit**                   **73696**                        **150kDa**                       **24**                           **1436**           **22%**
  *gi\|488170470*                                                                                    *hypothetical protein*                                                                        *57kDa*                          *71*                             *1394*             *20%*
  **gi\|6977941**                                                                                    **App protein**                                                                               **160kDa**                       **7**                            **425**            **7%**
  **gi\|915797040**                                                                                  **adhesin**                                                                                   **160kDa**                       **6**                            **390**            **6%**
  ** gi\|83270238**                                                                                  **AusI**                                                                                      **158kDa**                       **4**                            **288**            **4%**
   gi\|389605917                                                                                     NAD(P) transhydrogenase subunit alpha                        α522                             54kDa                            2                                162                2%
  **gi\|488141712**                                                                                  **carbon starvation protein A**                                                               **75kDa**                        **3**                            **146**            **3%**
  gi\|896381024                                                                                      hypothetical protein                                                                          57kDa                            8                                119                2%
  gi\|488158877                                                                                      hypothetical protein                                                                          147kDa                           2                                109                2%
  gi\|254672742                                                                                      alanine or glycine: cation symporter, AGCS family            α275                             45kDa                            2                                109                1%
  2\. Protein identified from the photocrosslinking products for a molecular weight around 140kDa.                                                                                                                                                                                      
  **Accession number**                                                                               **Protein name**                                             ***N*. *meningitidis* strain**   **Estimated Molecular weight**   **Number of matched peptides**   **MASCOT score**   **Sequence coverage**
  *gi\|325136153*                                                                                    *hypothetical protein NMBM0579_0886*                         *NMBM0579_0886*                  *57kDa*                          *80*                             *1852*             *25%*
  *gi\|120866758*                                                                                    *hypothetical protein NMC1281*                               *FAM18*                          *56kDa*                          *69*                             *1863*             *23%*
  gi\|501178984                                                                                      DNA-directed RNA polymerase β subunit                                                         154kDa                           28                               1808               27%
  *gi\|325140435*                                                                                    *hypothetical protein NMBCU385_0826*                         *CU385*                          *57kDa*                          *72*                             *1803*             *22%*
  *gi\|325144519*                                                                                    *hypothetical protein*                                       *NMBM01240013_0931*              *57kDa*                          *78*                             *1782*             *24%*
  *gi\|488171514*                                                                                    *hypothetical protein*                                                                        *57kDa*                          *70*                             *1656*             *23%*
  *gi\|488170470*                                                                                    *hypothetical protein*                                                                        *57kDa*                          *54*                             *1267*             *18%*
  gi\|488186495                                                                                      hypothetical protein                                                                          147kDa                           12                               800                12%
  gi\|488186095                                                                                      immunoglobulin A1 protease                                                                    121kDa                           9                                653                9%
  **gi\|488151215**                                                                                  **peptidylprolyl isomerase**                                                                  **56kDa**                        **8**                            **500**            **8%**
  gi\|316985319                                                                                      filamentous hemagglutinin family N-terminal domain protein   H44/76                           261kDa                           8                                496                8%
  **gi\|488154218**                                                                                  **heme biosynthesis operon protein HemX**                                                     **48kDa**                        **7**                            **490**            **7%**
  **gi\|488151215**                                                                                  **peptidylprolyl isomerase**                                                                  **56kDa**                        **8**                            **465**            **8%**
  **gi\|488146114**                                                                                  **D-lactate dehydrogenase**                                                                   **64kDa**                        **5**                            **363**            **5%**
  **gi\|389605276**                                                                                  **UPF0141 inner membrane protein yhjW**                                                       **62kDa**                        **6**                            **351**            **5%**
  gi\|488170091                                                                                      peptidase                                                                                     200kDa                           3                                202                3%
  **gi\|120866107**                                                                                  **putative protein-export membrane protein**                 **FAM18**                        **66kDa**                        **3**                            **176**            **3%**
  **gi\|732853**                                                                                     **IgA1 protease**                                                                             **54kDa**                        **3**                            **168**            **3%**
  **gi\|488141712**                                                                                  **carbon starvation protein A**                                                               **74kDa**                        **3**                            **165**            **3%**
  gi\|316985875                                                                                      4Fe-4S binding domain protein                                                                 146kDa                           3                                150                3%
  **gi\|389605917**                                                                                  **NAD(P) transhydrogenase subunit α**                                                         **54kDa**                        **2**                            **140**            **2%**
  **gi\|488141355**                                                                                  **arginine decarboxylase**                                                                    **71kDa**                        **2**                            **129**            **2%**
  gi\|349520                                                                                         pilus structural subunit, partial                                                             17kDa                            2                                128                2%
  **gi\|488143525**                                                                                  **protein translocase component YidC**                                                        **60kDa**                        **2**                            **125**            **2%**
  **gi\|254670993**                                                                                  **1-deoxy-D-xylulose 5-phosphate synthase**                                                   **69kDa**                        **2**                            **114**            **2%**
  **gi\|304337210**                                                                                  **methionine-R-sulfoxide reductase**                                                          **59kDa**                        **2**                            **112**            **2%**
  gi\|4838369                                                                                        NatD                                                                                          52kDa                            2                                109                2%
  3\. Protein identified from the photocrosslinking products for a molecular weight around 85kDa.                                                                                                                                                                                       
  **Accession number**                                                                               **Protein name**                                             ***N*. *meningitidis* strain**   **Estimated Molecular weight**   **Number of matched peptides**   **MASCOT score**   **Sequence coverage**
  gi\|2460281                                                                                        outer membrane protein Omp85                                                                  88kDa                            63                               2799               41%
  gi\|488170971                                                                                      membrane protein                                                                              88kDa                            58                               2599               38%
  *gi\|325136153*                                                                                    *hypothetical protein NMBM0579_0886*                                                          *57kDa*                          *63*                             *1774*             *24%*
  *gi\|325144519*                                                                                    *hypothetical protein NMBM01240013_0931*                                                      *57kDa*                          *60*                             *1692*             *23%*
  *gi\|488171514*                                                                                    *hypothetical protein*                                                                        *57kDa*                          *56*                             *1619*             *22%*
  *gi\|488174415*                                                                                    *hypothetical protein*                                                                        *57kDa*                          *56*                             *1577*             *22%*
  gi\|325141117                                                                                      LPS-assembly protein LptD                                    CU385                            87kDa                            21                               1440               19%
  gi\|488147360                                                                                      elongation factor G                                                                           77kDa                            27                               1398               20%
  gi\|325141117                                                                                      putative organic solvent tolerance protein                   CU385                            87kDa                            20                               1149               18%
  gi\|409107079                                                                                      type IV pilus biogenesis and competence protein PilQ                                          80kDa                            17                               973                15%
  gi\|209363328                                                                                      hemoglobin receptor, partial                                                                  87kDa                            16                               909                14%
  gi\|488154195                                                                                      ATP-dependent Clp protease ATP-binding subunit ClpA                                           85kDa                            21                               905                16%
  gi\|30017077                                                                                       TonB-dependent siderophore receptor FetA                                                      73kDa                            14                               793                13%
  gi\|120866913                                                                                      RNA polymerase sigma factor                                                                   75kDa                            11                               616                10%
  gi\|325142240                                                                                      2-oxoglutarate dehydrogenase E1 component                                                     102kDa                           10                               496                8%
  gi\|488150134                                                                                      GNAT family N-acetyltransferase                                                               89kDa                            7                                421                7%
  [gi\|496712676]{.ul}                                                                               [fimbrial protein]{.ul}                                                                       [18kDa]{.ul}                     [9]{.ul}                         [307]{.ul}         [4%]{.ul}
  gi\|645213765                                                                                      peptidase                                                                                     88kDa                            5                                295                5%
  **gi\|402319479**                                                                                  **hypothetical protein NMEN93004_1215**                                                       **18kDa**                        **6**                            **294**            **5%**
  gi\|488144915                                                                                      phosphoenolpyruvate synthase                                                                  87kDa                            5                                293                5%
  gi\|254673965                                                                                      putative efflux system transmembrane protein                                                  113kDa                           5                                249                4%
  gi\|496706569                                                                                      transferrin-binding protein 2                                                                 74kDa                            5                                239                4%
  gi\|896272027                                                                                      pilus assembly protein PilQ                                                                   75kDa                            5                                222                4%
  **gi\|45245**                                                                                      **periplasmic iron-binding protein**                                                          **34kDa**                        **4**                            **204**            **4%**
  gi\|121052755                                                                                      GTP pyrophosphokinase                                                                         86kDa                            3                                199                3%
  -------------------------------------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------- -------------------------------- -------------------------------- ------------------ -----------------------

Proteins shown in italics corresponds to the PamA protein itself.

Proteins shown in bold indicates the candidates examined for crosslinking to PamA K278(*p*BPa) in *N*. *meningitidis* by constructing the FLAG-tagged candidate mutants, but the crosslinking could not be detected.

The protein shown underlined is PilE crosslinked to PamA K278(*p*BPa) in *N*. *meningitidis*, which was confirmed in this study.

We then characterized the 85-kDa band, which could contain an approximately 20 kDa endogenous protein crosslinked to PamA K278(*p*BPa). LC-MS/MS followed by MASCOT analyses revealed two possible candidates, a fimbrial protein (17 kDa) and the hypothetical protein NMEN93004_1215 (18 kDa) ([Table 3](#pone.0237883.t003){ref-type="table"}). The BLAST homology search indicated that while we could not find any protein corresponding to NMEN93004_1215 in the databases, the fimbrial protein (accession number gi\|496712676) was 95% identical to the protein NMBH4476_0018 annotated as "type IV pilus assembly protein PilA" in *N*. *meningitidis* strain H44/76 with the highest E-value ([Table 3](#pone.0237883.t003){ref-type="table"}). Further computational analyses revealed that the "PilA protein" annotated in GenBank was 96% identical to PilE, a major component of meningococcal pili (reviewed in \[[@pone.0237883.ref017]\]). To confirm that the 85-kDa complex was composed of PilE and K278(*p*BPa)-Strep~2~-His~6~, we constructed the *pilE-FLAG N*. *meningitidis* strain HT2095 and examined the crosslinked samples by Western blotting with an anti-FLAG mAb ([Fig 5C](#pone.0237883.g005){ref-type="fig"}). The analysis revealed that PilE-FLAG was present in the 85-kDa band, with dependence on *p*BPa and UV irradiation ([Fig 5C](#pone.0237883.g005){ref-type="fig"}). We further examined crosslinked samples from the wild-type (HT1940 harboring pHT1388) and *pilE*-insertional mutant (HT2014 harboring pHT1388) by Western blotting with anti-PilE rabbit serum \[[@pone.0237883.ref033]\] ([Fig 5D](#pone.0237883.g005){ref-type="fig"}). The 85-kDa band was also observed with anti-PilE rabbit serum in the *pilE*^*+*^ genetic background only with *p*BPa and UV irradiation. Considering these results, we conclude that the 85-kDa band contains the PilE protein, indicating that PamA interacts with PilE in *N*. *meningitidis*.

Mapping the amino acid residue in PilE that crosslinks to the PamA protein {#sec020}
--------------------------------------------------------------------------

To further clarify the interaction between PamA and PilE, we attempted to identify the amino acid residue of PilE that crosslinks with PamA K278*(p*BPa). Since mapping was difficult and tedious \[[@pone.0237883.ref042]\], particularly for the endogenous proteins, the examination was conducted with recombinant proteins in *E*. *coli*.

We examined the interaction of two truncated recombinants, ΔN-PamA K278amb fused to maltose-binding protein (MBP) (MBP-ΔN-PamA K278amb) and ΔN-PilE with six glutamines (Gln~6~) in *E*. *coli* ([S6 Fig](#pone.0237883.s006){ref-type="supplementary-material"}). The crosslinked complex between MBP-ΔN-PamA K278(*p*BPa) and Gln~6~-ΔN-PilE was purified from *E*. *coli* and investigated using a gel-based proteomic analysis with LC-MS/MS ([S7](#pone.0237883.s007){ref-type="supplementary-material"}--[S9](#pone.0237883.s009){ref-type="supplementary-material"} Figs) \[[@pone.0237883.ref042]\]. The peptides containing *p*BPa (IEVGK\*\[*p*BPa\]LAFSTK), corresponding to aa 639 to 650 of MBP-ΔN-PamA K278(*p*BPa) (corresponding to aa 274 to 284 of native PamA), from crosslinked and uncrosslinked samples were analyzed by MS/MS. As shown in [S9 Fig](#pone.0237883.s009){ref-type="supplementary-material"}, the sequence was read from the annotated b and y ions of a crosslinked peptide until isoleucine (Ile) at position 19. This result indicated that the region around Ile19 in Gln~6~-ΔN -PilE is the site crosslinked to K278(*p*BPa) in MBP-ΔN-PamA.

Genetic elucidation of the interaction between PamA and PilE in *N*. *meningitidis* and its important for meningococcal internalization into HBMEC {#sec021}
--------------------------------------------------------------------------------------------------------------------------------------------------

Ile at position 19 in Gln~6~-ΔN-PilE corresponded to position 12 in native PilE in *N*. *meningitidis* ([S10 Fig](#pone.0237883.s010){ref-type="supplementary-material"}) because prepilin is processed by the prepilin peptidase PilD during translocation at the IM in *N*. *meningitidis* \[[@pone.0237883.ref036], [@pone.0237883.ref067]\]. Multiple alignments showed that the N-terminal region of PilE around Ile12 is highly conserved among neisserial species, including *N*. *gonorrhoeae* and *N*. *lactamica*, implicating the importance of the region in PilE ([S10A Fig](#pone.0237883.s010){ref-type="supplementary-material"}) \[[@pone.0237883.ref068]\].

To further examine the functional interaction between PamA and the region containing the PilE I12 residue in *N*. *meningitidis*, the meningococcal *pilE I12A-cat* mutant HT2167 was constructed ([Table 1](#pone.0237883.t001){ref-type="table"}), and we monitored its infectious ability and the accompanying host cell's cytoskeleton rearrangement by the localization of ezrin. The *pilE I12A N*. *meningitidis* mutant was less efficiently internalized into HBMEC, while the adhesion remained unchanged ([Fig 6A](#pone.0237883.g006){ref-type="fig"}), and ezrin did not accumulate beneath the *pilE I12A-cat* mutant ([Fig 6B](#pone.0237883.g006){ref-type="fig"}). Western blotting with UV-irradiated samples purified from HT2167 expressing the *MmpBPaRS/T* and *pamA K278amb* genes also confirmed that the interaction between PilE and PamA K278(*p*BPa) is markedly reduced by the *pilE I12A* mutation ([Fig 6C](#pone.0237883.g006){ref-type="fig"}), providing genetic evidence for the interaction between PamA and PilE in *N*. *meningitidis*. Furthermore, since the phenotypes appeared to be mostly identical to that of the *ΔpamA N*. *meningitidis* mutant (Figs [1](#pone.0237883.g001){ref-type="fig"} and [6A](#pone.0237883.g006){ref-type="fig"}), these results indicated that PamA and PilE interact functionally with each other in *N*. *meningitidis* and that this interaction is important for meningococcal infection in HBMEC.

![The *pilE I12A N*. *meningitidis* mutant also showed reduced internalization into HBMEC, the induction of cytoskeleton rearrangements, and interactions with PamA *in N*. *meningitidis*.\
(A) A I12A mutation in the *pilE* gene affects *N*. *meningitidis* internalization into HBMEC. Adherence (white) and internalization (gray) of *N*. *meningitidis* strains in HBMEC. Each value is the mean ± standard error of the mean (CFU per 10^4^ HBMEC) from at least four experiments. The bars indicate the bacterial numbers of *N*. *meningitidis* wild-type *pamA*^*+*^ (HT1125, left), *ΔpamA*::*spc* (HT1822, middle-left), *pilE*^*+*^*-cat* (HT1744 middle-right), and *pilE I12A-cat* (HT2167, right), respectively (see [S1 Table](#pone.0237883.s014){ref-type="supplementary-material"}). \**P*\<0.01, \*\**P*\<0.02, significantly different from the *pamA*^*+*^ strain or *pilE*^*+*^*-cat* strain. (B) Immunofluorescence microscopy showing the accumulation of ezrin beneath *N*. *meningitidis* strains. The HBMEC monolayer was infected with wild-type *pilE*^*+*^*-cat* (middle) and *pilE I12A-cat* (right) *N*. *meningitidis* strains. A non-infected HBMEC monolayer is also shown in the left panels. Bacteria and HBMEC were observed by phase-contrast microscopy (upper panels). Ezrin was immunostained with anti-ezrin mAb and Alexa Fluor 488-conjugated rabbit anti-mouse IgG (green channel, lower panels). (C) PilE I12A was crosslinked to PamA K278(*p*BPa) less efficiently than wild-type PilE in *N*. *meningitidis*. Black and red arrows show the crosslinked complex between PamA K278(*p*BPa) and PilE, and the gray arrow indicates an unidentified band that crossreacted with anti-PilE rabbit serum. +/- indicates the presence or absence of the *pilE* gene, respectively.](pone.0237883.g006){#pone.0237883.g006}

Characterization of pili in the *ΔpamA N*. *meningitidis* mutant {#sec022}
----------------------------------------------------------------

The results described above suggested that PamA affects the functions of meningococcal pili, resulting in a negative impact on meningococcal infection in HBMEC. To further clarify the effects of PamA on pili, we investigated the function of pili in *N*. *meningitidis*. Electron microscopy with negative staining showed that the *ΔpamA N*. *meningitidis* mutant was similarly piliated to the wild-type strain HT1125 ([S11A Fig](#pone.0237883.s011){ref-type="supplementary-material"}, left and middle-left). Meningococcal pili are known to play a role not only in the infection of host cells \[[@pone.0237883.ref017], [@pone.0237883.ref069]\], but also in meningococcal natural competence, switching motility, and aggregation \[[@pone.0237883.ref070], [@pone.0237883.ref071]\]. An examination of pilus function in natural competence and aggregation revealed that the pili of the *ΔpamA N*. *meningitidis* mutant retain similar functions to those of the wild-type *pilE N*. *meningitidis* strain ([S11B and S11C Fig](#pone.0237883.s011){ref-type="supplementary-material"}). These results suggest that PamA does not participate in pilus formation itself or in functions related to natural competence and aggregation. It is important to note that the *pilE I12A-cat N*. *meningitidis* mutant is also as functional as the wild-type *pilE-cat N*. *meningitidis* strain while its piliation number its apparently smaller possibly due to translational fusion with the *cat* gene ([S11 Fig](#pone.0237883.s011){ref-type="supplementary-material"} and [Fig 6](#pone.0237883.g006){ref-type="fig"}).

We examined the effects of PamA on meningococcal pili in more detail. Although the main component of the meningococcal pilus is PilE, its formation requires more than 20 proteins \[[@pone.0237883.ref072]--[@pone.0237883.ref074]\]. To investigate the effects of the *pamA* mutation on pili, we initially assessed the pilus protein levels in HT1125 and HT1822 using LC-MS/MS with Tandem Mass Tag (TMT) labeling \[[@pone.0237883.ref038]\] ([S5 Table](#pone.0237883.s018){ref-type="supplementary-material"}), and found that the amounts of some pilus components appeared to differ between HT1125 and HT1822. However, accurate comparisons of the protein amounts, particularly that for PilE, by TMT are methodologically difficult because *N*. *meningitidis* has 8 non-expressed *pilS* genes \[[@pone.0237883.ref075]\], according to the deduced amino acids recorded as Protein in the database. Therefore, we directly monitored the contents of pilus components, particularly for three minor pilins: PilX for aggregation in and adherence to human cultured cells \[[@pone.0237883.ref071], [@pone.0237883.ref076], [@pone.0237883.ref077]\], PilV to trigger plasma membrane reorganization \[[@pone.0237883.ref036], [@pone.0237883.ref071], [@pone.0237883.ref078]\], and ComP for natural competence \[[@pone.0237883.ref079]\]. PilF, PilM, and PilP, located on the meningococcal inner membrane for pilus formation \[[@pone.0237883.ref008], [@pone.0237883.ref067], [@pone.0237883.ref069], [@pone.0237883.ref080], [@pone.0237883.ref081]\], were also monitored. The relative amounts of the components to the PilE subunit in purified pili were measured by Western blotting followed by quantification ([Fig 7](#pone.0237883.g007){ref-type="fig"}). The relative ratios of PilF, PilP, and PilM to PilE did not significantly differ between the *ΔpamA* and wild-type *N*. *meningitidis* strains. On the other hand, in *ΔpamA* pili the relative amount of PilV increased, whereas that of PilX decreased ([Fig 7A](#pone.0237883.g007){ref-type="fig"}). It is important to note that the amount of ComP was too low in the whole cell extract or purified pili to detect by WB, even when the *comP-FLAG N*. *meningitidis* strain or anti-ComP rabbit antiserum was used (data not shown). We also confirmed that the expressions of PilE, PilV, and PilX-FLAG were not affected by the *ΔpamA* mutation ([Fig 7B](#pone.0237883.g007){ref-type="fig"}). Considering these results, the *pamA* mutation may cause unusual proportions of PilV and PilX to PilE in meningococcal pili, probably by improper sorting of PilE during pili formation, which might affect meningococcal infection in human cultured cells.

![Disruption of the interaction between PamA and PilE leads to abnormal proportions of PilV and PilX relative to PilE in meningococcal pili.\
(A) Ratio of pilus components to PilE in purified pili. The relative amounts of PilF-FLAG (HT2218 and HT2219), PilP-FLAG (HT2136 and HT2137), PilM-HA (HT2132 and HT2133), PilV (HT1125 and HT1822), and PilX-FLAG (HT2211 and HT2212) to PilE in purified pili were measured by Western blotting with appropriately diluted samples followed by quantification of the band intensity using the 30-kDa band in the molecular marker as an internal golden standard. The values obtained were divided by the value of PilE in the same sample. The significance of differences was examined by the t-test. (B, C, D) The *pamA* mutation does not affect the expression of the PilE (B), PilV (C), or PilX-FLAG (D) protein in *N*. *meningitidis*. Bacterial extracts equivalent to OD~600~ value of 0.0025 (for PilE) or 0.05 (for PilV and PilX-FLAG) were analyzed by Western blotting with anti-PilE and anti-PilV rabbit sera, and an anti-FLAG mAb, respectively. Black arrows indicate PilE, PilV, and PilX-FLAG, respectively.](pone.0237883.g007){#pone.0237883.g007}

Discussion {#sec023}
==========

While progressive genome sequencing has recently provided novel insights into *N*. *meningitidis*, more than 50% of the annotated ORFs remain as "hypothetical proteins", and their biological functions are currently unclear. This may be due to an incomplete understanding of meningococcal pathogenesis, which is largely attributable to the lack of analytical methods for *N*. *meningitidis* \[[@pone.0237883.ref034]\]. While the results of our genetic analyses indicated that the hypothetical protein NMB1345 (renamed PamA in the present study) in *N*. *meningitidis* plays an important role in meningococcal internalization into human cultured cells, the novel methodologies currently available for meningococci did not provide any insights into the function of PamA in *N*. *meningitidis*. Therefore, the incorporation of photoreactive ncAAs by pyrrolysine-based amber suppression was applied to a meningococcal protein with an unknown function, which implicated its physiological function in *N*. *meningitidis*.

The incorporation of ncAAs by pyrrolysine-based amber suppression has been used for site-specific incorporation into target proteins *in vivo* in a broad range of species from *E*. *coli* to eukaryotic systems (reviewed in \[[@pone.0237883.ref041]\]). However, regarding pathogenic bacteria, only a few studies have successfully incorporated ncAAs into EPEC \[[@pone.0237883.ref082]\], *Shigella flexinelli* \[[@pone.0237883.ref082]\], *Salmonella typhimurium* \[[@pone.0237883.ref083]\], *M*. *tuberculosi*s \[[@pone.0237883.ref084]\], and *B*. *cereus* \[[@pone.0237883.ref085]\]. Moreover, these bacteria were only subjected to examinations of the incorporation of ncAAs into a well-characterized protein (e.g. GST or GFP), with a low molecular mass (approx. 10 kDa) and a known function \[[@pone.0237883.ref086]\], or a peptide \[[@pone.0237883.ref085]\], produced from expression vectors. Moreover, X-ray structure information for target proteins will also be advantageous for photoreactive ncAAs incorporation because the proper positions to incorporate ncAAs may be more easily predicted. Even when the X-ray structure of a target protein is unknown, a lower molecular mass is more advantageous because it is easier to scan the optimal site for ncAA incorporation in the target protein. Therefore, genetic photocrosslinker incorporation has not yet been applied to analyze a protein with unknown function or three-dimensional structure is unknown. Furthermore, some disadvantages in the application of photocrosslinking ncAAs incorporation combined with MS to *Neisseria* species are the very few expression vectors for neisseriae \[[@pone.0237883.ref033], [@pone.0237883.ref034]\] \[[@pone.0237883.ref087]\] and the limited culture methods in liquid medium due to autolysis \[[@pone.0237883.ref088]\]. To the best of our knowledge, this is the first study to demonstrate the incorporation of ncAAs into *N*. *meningitidis*. Moreover, after observing that ncAA-incorporated GST proteins are crosslinked as the dimer form in *N*. *meningitidis* ([Fig 3E](#pone.0237883.g003){ref-type="fig"}), we incorporated *p*BPa into the PamA protein in *N*. *meningitidis* ([S5 Fig](#pone.0237883.s005){ref-type="supplementary-material"}) and found that this meningococcal hypothetical protein with no physiological and structural information is closely associated with PilE *in N*. *meningitidis*.

Our strategy of incorporating a genetic photocrosslinker coupled with MS in *N*. *meningitidis* revealed that the meningococcal hypothetical protein PamA is associated with PilE *in N*. *meningitidis*. Further physicochemical analyses with PamA and PilE recombinants in *E*. *coli* identified the crosslinked regions between PamA K278(*p*BPa) PilE ([S7](#pone.0237883.s007){ref-type="supplementary-material"}--[S9](#pone.0237883.s009){ref-type="supplementary-material"} Figs), and genetic analyses using the *pilE I12A N*. *meningitidis* mutant suggested that the interaction between PamA and PilE in *N*. *meningitidis* is functionally important for meningococcal pilus formation and infection to HBMEC ([Fig 6](#pone.0237883.g006){ref-type="fig"}). While further studies are needed, the PamA interaction with the N-terminal region of PilE around the Ile12 residue ([S10 Fig](#pone.0237883.s010){ref-type="supplementary-material"}) may be important to maintain the function of meningococcal pili by PamA *in N*. *meningitidis*.

The function of meningococcal PamA has not been clearly discerned in this study. The present results showed that PamA is not required for pilus formation itself ([S11A Fig](#pone.0237883.s011){ref-type="supplementary-material"}) but participates to keep optimal proportions of PilV and PilX to PilE in meningococcal pili ([Fig 7](#pone.0237883.g007){ref-type="fig"}). This result does not seem to contradict previous findings showing that the proper ratio of PilV and PilX to PilE in pili leads to pilus conformational changes that trigger plasma membrane reorganization \[[@pone.0237883.ref036], [@pone.0237883.ref071], [@pone.0237883.ref078], [@pone.0237883.ref076], [@pone.0237883.ref077]\]. However, we could not eliminate the possibility that more essential dysregulation(s) other than the imbalance of PilV and PilX to PilE in meningococcal pili by the *pamA* mutant were not identified in this study. We focused on three bands crosslinked with PamA K278(*p*BPa) with the highest intensity among the five PamA K-amb (*p*BPa) mutants, while the interaction between PamA and PilE found was identified from a band with the lowest intensity ([Fig 4](#pone.0237883.g004){ref-type="fig"}). On the other hand, the two protein complexes with the highest intensities (approximately 150 and 140 kDa) crosslinked to PamA K278(*p*BPa) were not identified in any protein other than PamA itself by peptide mass fingerprinting ([Table 3](#pone.0237883.t003){ref-type="table"}). Although further analyses are needed, the two bands appeared to correspond to the homotrimer of PamA because intramolecular crosslinking was also detected in the MBP-ΔN-PamA K278(*p*BPa) recombinant protein in *E*. *coli* ([S12 Fig](#pone.0237883.s012){ref-type="supplementary-material"}). The endogenous proteins crosslinked to the PamA K208(*p*BPa), PamA K341(*p*BPa), PamA K382(*p*BPa), and PamA K395(*p*BPa) mutants have yet to be identified ([Fig 4](#pone.0237883.g004){ref-type="fig"}) and their characterization will provide more information about the novel function of PamA in *N*. *meningitidis*.

Surprisingly, unidentified genes involved in pilus function are still being discovered, although more than 20 proteins involved in pilus synthesis and function have already been identified by genetic \[[@pone.0237883.ref072]--[@pone.0237883.ref074]\] and WGS \[[@pone.0237883.ref032], [@pone.0237883.ref039]\] analyses. Therefore, our strategy using genetic screening by STM combined with genetically-encoded photocrosslinking amino acid incorporation and an MS analysis, could be a powerful method to identify new pathogenic factors in *N*. *meningitidis*. BLAST searches revealed *pamA* gene homologues in only three neisserial species: *N*. *meningitidis*, *N*. *gonorrhoeae*, and *N*. *lactamica* ([S13 Fig](#pone.0237883.s013){ref-type="supplementary-material"}). *N*. *meningitidis* and *N*. *gonorrhoeae* are closely related bacterial pathogens that share many common genes with a high degree of sequence identity (typically greater than 95%), and DNA relatedness studies clustered commensal *N*. *lactamica* with these two pathogenic *Neisseria spp*. \[[@pone.0237883.ref089]\]. Since the sequences of the *pamA* genes appeared to be more divergent among the three species than within *N*. *meningitidis* ([S13 Fig](#pone.0237883.s013){ref-type="supplementary-material"}), the *pamA* gene may have been acquired at a later stage of evolution by the three neisserial species, and the restricted possession of the *pamA* gene in the three neisserial species may reflect the physiological function of PamA.

While further studies are needed to clarify the functions of PamA in *Neisseria*, it is important to note that the application of new methodology to *N*. *meningitidis* provided novel insights into the physiological function of a meningococcal hypothetical protein with no obvious information such as its predicted biological function or three-dimensional structure. Our established system for ncAA incorporation by pyrrolysine-based amber suppression into *N*. *meningitidis* will facilitate a broad range of *N*. *meningitidis* studies, particularly the mapping of protein-protein interaction networks or characterization of the functions of hypothetical proteins *in vivo*. Nevertheless, as shown in the present study, *in vivo* research involving the combination of STM and photoreactive ncAAs incorporation by pyrrolysine-based amber suppression with an MS analysis will reveal meningococcal virulence factors that are difficult to identify using most currently available methods. The ncAA incorporation system described in the present study may become one of the strongest driving advancements for studies on meningococcal biology, pathogenesis, and vaccine development.

Supporting information {#sec024}
======================

###### Nucleotide sequence and deduced amino acid sequence of the *pamA* gene in *N*. *meningitidis* HT1125 strain.

(GenBank Accession No LC511747). Lysine (K) residues are shown in red and the K residues replaced with amber codons in this study are indicated in bold red. Positions of K residues are shown as blue numbers. The grey bar indicates the putative hydrophobic region identified by SOSUI \[[@pone.0237883.ref090]\], which region were deleted to construct the PamA recombinants in *E*. *coli* in this study.

(PDF)

###### 

Click here for additional data file.

###### Photocrosslinking of PamA K148(*m*AzZLys), K273(*m*AzZLys), and K388(*m*AzZLys) in *N*. *meningitidis*.

\(A\) Detection of PamA K148amb, K273 and K388amb expressed by pyrrolysine-based amber suppression with *m*AzZLys in *N*. *meningitidis*. Bacteria grown on one-fourth of a GC agar plate in the presence or absence of 0.3 mM *m*AzZLys and extracts equivalent to OD~600~ of 0.1 were analyzed by Western blotting with anti-PamA rabbit serum. +/- indicates the presence or absence of *m*AzZLys. The black arrow shows the full-length PamA protein. (B) Detection of complexes containing PamA K(*m*AzZLys) crosslinked to an endogenous protein in *N*. *meningitidis*. Bacteria grown on one-fourth of a GC agar plate in the presence of 0.3 mM *m*AzZLys were crosslinked by UV light irradiation, and mixed with SDS buffer. Aliquots were analyzed by Western blotting with an anti-His~6~ mAb. +/- indicates presence or absence of *m*AzZLys (upper), treatment or nontreatment with UV irradiation (lower). Black and grey arrows show the full-length PamA protein and putative complexes corresponding to PamA K(*m*AzZLys) crosslinked to an endogenous protein, respectively.

(PDF)

###### 

Click here for additional data file.

###### PamA K278(*p*BPa) protein crosslinks with endogenous proteins in *N*. *meningitidis*.

UV crosslinking of 27 PamA K-amb mutants expressed by pyrrolysine-based amber suppression with *p*BPa in *ΔpamA N*. *meningitidis*. The black arrow shows the full-length PamA K-amb protein expressed by pyrrolysine-based amber suppression with *p*BPa. PamA K-amb mutants shown in red were subjected to a more detailed analysis in [Fig 4](#pone.0237883.g004){ref-type="fig"}.

(PDF)

###### 

Click here for additional data file.

###### Schematic structure of the C-terminal region of PamA K278-Strep~2~-His~6~.

\(A\) Amino acid sequence of the C-terminal region of PamA K278-Strep~2~-His~6~. (B) Nucleotide sequence of the C-terminal region of PamA K278-Strep~2~-His~6.~ The same colors in A and B corresponds to the same region in amino acid (A) and nucleotide (B) sequences.

(PDF)

###### 

Click here for additional data file.

###### Mass spectrometry analysis of PamA K278amb expressed by the pyrrolysine-based amber suppression with *p*BPa in *N*. *meningitidis*.

\(A\) Amino acid sequence of PamA with Strep~2~-His~6~ tag at C-terminus. The tryptic peptide containing a ncAA, *p*BPa is highlighted in red and the *p*BPa at position 278 is represented as X. (B) The incorporation of *p*BPa at position 278 was confirmed by MALDI-TOF MS analysis of the tryptic peptide IEVGXLAFSTK (X represents *p*BPa). The observed (obsd) molecular masses agreed well with the calculated (calcd) masses. (C) MALDI-TOF MS/MS analysis of the tryptic peptide of shown in B. Tandem mass spectrum of the peptide IEVGXLAFSTK (X = *p*BPa). The sequence can be read from the annotated b (red) or y (blue) ion series.

(PDF)
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Click here for additional data file.

###### Examination of purified MBP-ΔN-PamA K278(*p*BPa) and Gln~6~-ΔN-PilE recombinant proteins from *E*. *coli* strains for LC-MS/MS analysis.

Recombinant proteins crosslinked in *E*. *coli* were purified with amylose resin and concentrated to 500 μl as described in the Materials and Methods. Aliquots (approximately 1 μl) were fractionated by SDS-PAGE and analyzed by staining with a CBB staining kit (A), and Western blotting with anti-MBP (B) and anti-His~6~ (C) mAbs. Prestained molecular mass standards are shown by grey numbers with asterisks, since the apparent molecular masses were different from the actual masses due to abnormal mobility in the gel. +/- indicates treatment or non-treatment with UV irradiation, respectively. Black, blue and red arrows indicate PamA ΔN-K278amb (no pyrrolysine-based amber suppression with *p*BPa), PamA ΔN-K278(*p*BPa)-Strep~2~-His~6~ (full-length) and the complex crosslinked between PamA K278(*p*BPa)-Strep~2~-His~6~ and ΔN-Gln~6~-PilE, respectively. (D) Schematic figure of the crosslinking between PamA ΔN-K278(*p*BPa)-Strep~2~-His~6~ and Gln~6~-ΔN-PilE recombinant proteins in *E*. *coli*.

(PDF)

###### 

Click here for additional data file.

###### Analysis of amino acid residues (region) in PilE crosslinked to PamA K278 (*p*BPa) by LC-MS/MS.

\(A\) Liquid chromatogram of uncrosslinked MBP-ΔN-PamA K278(*p*BPa) and the Gln~6~-ΔN-PilE protein (upper), and the complex crosslinked between MBP-ΔN-PamA K278(*p*BPa) and Gln~6~-ΔN-PilE (lower). The fraction eluted at 12.38 min from the uncrosslinked sample contained the peptide IEVGK(*p*BPa)LAFSTK corresponding to position 639 to 650 of MBP-ΔN-PamA K278(*p*BPa) (positions 274 to 284 for native PamA), determined by an MS analysis. (B) Enlarged liquid chromatogram after 14 min of elution. The fraction eluted at 17.32 min from the crosslinked sample contained the peptide `MQQQQQQFTLIELMIVIAIVGILAAVALPAYQDYTARAQVSEAILLAEGQK`, corresponding to the first 51 amino acids of Gln~6~-ΔN-PilE at the N terminus, which was crosslinked to the peptide IEVGK(*p*BPa)LAFSTK from the MBP-ΔN-PamA K278(*p*BPa) protein. (C) MS spectrum of the LC fraction eluted at 17.32 min that contained the cross-linked peptide between `MQQQQQQFTLIELMIVIAIVGILAAVALPAYQDYTARAQVSEAILLAEGQK` from Gln~6~-ΔN-PilE and IEVGK(*p*BPa)LAFSTK from MBP-ΔN-PamA K278(*p*BPa)(obsd:1380.9367 \[M+H\]^5+^).

(PDF)

###### 

Click here for additional data file.

###### MS/MS spectrum of the peptide IEVGK(*p*BPa)LAFSTK from MBP-ΔN-PamA K278(*p*BPa).

The sequence was read from the annotated b and y ion series; b3, y4, y5, y6, y7, y8, y9, and y10 ions were observed.

(PDF)

###### 

Click here for additional data file.

###### MS/MS spectrum of the cross-linked peptide between `MQQQQQQFTLIELMIVIAIVGILAAVALPAYQDYTARAQVSEAILLAEGQK` from Gln~6~-ΔN-PilE and IEVGK(*p*BPa)LAFSTK from MBP-ΔN-PamA K278(*p*BPa)(obsd:1380.9367 \[M+H\]^5+^).

The sequence was read from the annotated b and y ion series; b3, y4, y5, y6, y7, y8, y9, and y10 ions of the peptide IEVGK(*p*BPa)LAFSTK from MBP-ΔN-PamA K278(*p*BPa) (shown in red), and b3, b6, b9, b10, b11, b12, b13, b14, b15, b16, b17, b18, y4, y5, y6, y7, y8, y9, y10, y11, y12, y13, y14, y15, y16, y17, y18, y19, y20, y21, y22, y23, y24, y25, y26, y27, y28, y29, y30, y31, and y32 ions of the peptide `MQQQQQQFTLIELMIVIAIVGILAAVALPAYQDYTARAQVSEAILLAEGQK` from Gln~6~-ΔN-PilE (shown in blue) were observed.

(PDF)

###### 

Click here for additional data file.

###### Sequence alignment between neisserial PilE and crystal structure of full-length gonococcal PilE.

\(A\) Amino acid sequence alignment of PilE proteins from *N*. *meningitidis (Nm)*, *N*. *gonorrhoeae (Ng)* and *N*. *lactamica (Nl)*. The N-terminal half of the α-helix (α1-N) responsible for pilin assembly is shown by red (residues 1--14; α1:1--14) and cyan (residues 15--28; α1:15--28) bars, respectively. The αβ-loop, protruding from the globular domain to form a ridge on the subunit surface is indicated as a yellow bar. The D-region containing the hypervariable loop that protrudes as a second ridge on the globular domain is indicated as a light green bar. Red numbers indicate the positions of amino acids at which the functions of α1-N are divided. Ile at position 12 is indicated by a red vertical arrow. *N*. *meningitidis* HT1125 PilE (DDBJ accession no. AB698857), *N*. *meningitidis* H44/76 PilE (GenBank accession no. CP002420), *N*. *gonorrhoeae* MS11 PilE (EMBL accession no. CAI08338) and *N*. *lactamica* NLA_1780 type IV pilus assembly protein PilA (GenBank accession no. FN995097). (B) X-ray crystal structure of gonococcal PilE \[[@pone.0237883.ref091]\]. α1:1--14, α1:15--28, αβ-loop and D-region are shown in red, cyan, yellow and light green, respectively (the colors in B correspond to those in A). Ile at position 12 is indicated as a space-filling molecule.

(PDF)

###### 

Click here for additional data file.

###### Characterization of pili.

\(A\) Electron micrographs showing piliation of *N*. *meningitidis* strains HT1125 (wild-type), HT1822 (*ΔpamA*), HT1744 (*pilE*^*+*^*-cat*), and HT2167 (*pilE I12A-cat*). Upper and lower panels show magnifications of 20,000 and 50,000, respectively. Scale bars shown in black (upper) and white (lower) represent 200 nm. (B) Quantification of the competence for DNA transformation in *N*. *meningitidis* wild-type, and *pilE*^*-*^, *ΔpamA*, *pilE*^*+*^*-cat* and *pilE I12A-cat* mutants. Equivalent numbers of recipient cells were transformed using 0.5 μg of chromosomal DNA purified from the Nal^R^ (nalidixic acid resistant) strain HT1001, and Nal^R^ transformants were counted. Results are expressed as numbers of Nal^R^ transformants per 1 μg DNA and ± standard deviation from at least 8 independent experiments. (C) Aggregation as assessed by phase-contrast microscopy. Aggregates of *N*. *meningitidis* strains HT1125 (wild-type), HT1156 (*pilE*^*-*^), HT1822 (*ΔpamA*), HT1744 (*pilE*^*+*^*-cat*) and HT2167 (*pilE I12A-cat*) were observed after 4 hours of incubation in RPMI containing 10% fetal bovine serum.

(PDF)

###### 

Click here for additional data file.

###### Detection of homomeric crosslinking between two MBP-ΔN-PamA K278(*p*BPa).

MS/MS spectrum of the peptide IEVGK(*p*BPa)LAFSTK (at positions 274 to 284 for native PamA) crosslinked to LNELVNLVTDLQIGAFINPNGSIAPS (at positions 247 to 273 for native PamA) in MBP-ΔN-PamA K278(*p*BPa). The crosslinked site was analyzed by SIM-XL (<http://patternlabforproteomics.org/sim-xl>). The sequence can be read from the annotated b and y ion series: b3, y3, y4, y5, y6 ions of the peptide IEVGK(pBPa)LAFSTK from MBP-ΔN-PamA K278(*p*BPa) (shown in red), and b3, b4, b5, b6, b7, b8, b10, b13, b19, b21, y4, y5, y6, y7, y8, y9, y10, y11, y12, y13, y14, y15 ions of a peptide LNELVNLVTDLQIGAFINPNGSIAPS from MBP-ΔN-PamA K278(*p*BPa) (blue) were observed, respectively. We could not confirm whether *p*BPa at position 278 was crosslinked to Leu at position 257 or Gln at position 258 (shown in yellow overlay).

(PDF)

###### 

Click here for additional data file.

###### Phylogenetic tree showing the relation of *pamA* genes among neisserial species: *N*. *meningitidis*, *N*. *gonorrhoeae and N*. *lactamica*.

The *pamA* genes (the genes encoding "conserved hypothetical protein") from three neisserial species were analyzed by Molecular Evolutionary Genetics Analysis (MEGA) X \[[@pone.0237883.ref092]\]. The evolutionary history was inferred using the Neighbor-Joining method \[[@pone.0237883.ref093]\]. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the Maximum Composite Likelihood method \[[@pone.0237883.ref094]\] and are in the units of the number of base substitutions per site. The robustness of the NJ method was tested by bootstrapping with 500 replicates of data, and the percentages are shown at the nodes. This analysis involved 19 nucleotide sequences of genes encoding *N*. *meningitidis* HT1125 PamA (DDBJ accession no. LC511747), *N*. *meningitidis* H44/76 conserved hypothetical protein (GenBank accession no. CP002420), *N*. *meningitidis* MC58 hypothetical protein (GenBank accession no. AE002098), *N*. *meningitidis* M04-240196 conserved hypothetical protein (GenBank accession no. CP002423), *N*. *meningitidis* alpha14 conserved hypothetical protein (GenBank accession no. AM889136), *N*. *meningitidis* NZ-05/33 conserved hypothetical protein (GenBank accession no. CP002424), *N*. *meningitidis* M01-240149 conserved hypothetical protein (GenBank accession no. CP002421), *N*. *meningitidis* alpha710 hypothetical protein (GenBank accession no. CP001561), *N*. *meningitidis* 053442 conserved hypothetical protein (GenBank accession no. CP000381), *N*. *meningitidis* 8013 conserved hypothetical protein (GenBank accession no. FM999788), *N*. *meningitidis* M01-240355 conserved hypothetical protein (GenBank accession no. CP002422), *N*. *meningitidis* 510612 hypothetical protein (GenBank accession no. CP007524), *N*. *meningitidis* WUE2694 conserved hypothetical protein (GenBank accession no. FR774048), *N*. *meningitidis* G2136 conserved hypothetical protein (GenBank accession no. CP002419), *N*. *meningitidis* Z2491 hypothetical protein (GenBank accession no. AL157959), *N*. *meningitidis* FAM18 hypothetical protein (GenBank accession no. AM421808), *N*. *gonorrhoeae* FA1090 hypothetical protein (RefSeq accession no. NC_002946), *N*. *gonorrhoeae* NCCP11945 conserved hypothetical protein (GenBank accession no. CP001051) and *N*. *lactamica* putative secreted protein (GenBank accession no. FN995097).

(PDF)
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Click here for additional data file.

###### Oligonucleotides used in this study.

(DOCX)

###### 

Click here for additional data file.

###### Plasmids to construct *N*. *meningitidis* mutants.

(DOCX)

###### 

Click here for additional data file.

###### Plasmids for production of protein recombinants expressed in *E*. *coli*.

(DOCX)

###### 

Click here for additional data file.

###### IncQ plasmids for *N*. *meningitidis* strains which results were shown in supporting information.

(DOCX)

###### 

Click here for additional data file.

###### Analysis of Pili components by Tandem Mass Tag labeling.

Pili isolated from *N*. *meningitidis* strains HT1125 (wild-type) and HT1822 (*ΔpamA*) were subjected to trypsin digestion. Labelling of the peptides and analysis by LC-MS/MS were performed as described previously \[[@pone.0237883.ref038]\]. Proteins were identified by running MASCOT against the NCBI database (NCBInr 20160202). Ratio of the protein levels were expressed as the value of relative amount in HT1822 divided into those in HT1125. The results from four independent experiments were shown in this table.

(DOCX)

###### 

Click here for additional data file.

###### 

(PDF)

###### 

Click here for additional data file.

We thank Dr. Masatomo Morita for advice about phylogenetic analyses.
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Dear Dr. Takahashi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

After studying your manuscript, this academic editor found it confusing, poorly presented and not properly structured with lot of typos, style and grammatical errors. The both reviewers (independently) shared my view that the manuscript is in part difficult to comprehend and whole subject still requires to be substantially worked out (matured). Although one reviewer can even envisage a publication of the manuscript with the \"minor revision\"-- the second reviewer opted for the \"major revision\" and expects a significant improvement in both data presentation and rewriting of the manuscript. After balancing their comments and the literature-check, it is difficult to escape the fact that the work still needs substantial further improvements. Thus, we feel that it has merit, but is not suitable for publication as it currently stands. Therefore, my decision is \"Major Revision.\" We hope that criticism of the experts will help to improve the quality of your revised manuscript.

We would appreciate receiving your revised manuscript by Jul 02 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Ned Budisa

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

3\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

Additional Editor Comments:

I asked highly experted reviewers and observers in the field for a fair, unbiased and balanced review on your paper. Now their comments are available to you. While the referee 2 justifiably voiced general concerns about the (a) scientific style (manuscript structure and focus), (b) practical relevance and (c) good scientific presentation in general, the referee 1 had many highly relevant technical issues which urgently needed to be addressed. All these concerns must be addressed correctly (point-to-point) in the revised manuscript (only when these conditions are fully met, I can handle the manuscript again as an academic editor). Obviously, the work still needs substantial improvements. I feel that it has merit, but is not suitable for publication as it currently stands. Therefore, my decision is again \"Major Revision\" and I invite you to submit a revised version of the manuscript that addresses the points raised as elaborated above.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript has applied the genetic code expansion tools to reveal interaction of a hypothetical protein, NMB1345, to the PilE, a major component of meningococcal pili, in Neisseria meningiditis. Introduction of a new methodology to identify possible function of unknown factors in pathogenic bacteria is an interesting subject for further application of the orthogonal translation systems and create a new area of research. The manuscript has been prepared and written in scientific manner and just some minor issues has to be remained which mentioned below:

1- The quality of figures are very low and should be improved.

2- The number of figures is too high. Some of them could be moved in "Supporting information" part. For example, Fig. 4 and Fig. 7. Moreover, figures 5 and 6 should be combined.

3- There is some mistyping in the text. For example: line 86, "intarected!!"; line 110, "intection!!"; line 149 in Table 1, readjusting needed; line 635, double typing or moving after ref.; line 737, "seemd!!"

4- Line 122: "L plates"? Clarify.

5- Line 803: "proteins"; only one protein highlighted in red, but in the text two proteins mentioned. Delete "s" or highlight the second one (NMEN93004-1215).

6- In Fig. 3B: Western blotting would not be able to confirm proper incorporation of ncAA. The MS analysis should be done. Please clarify this issue in corresponding part.

7- The last but not least, please explain how chemically a protein like MBP-�N-PamA K278(pBPa) crosslinked to the endogenous proteins like Gln6-�N-PilE? Self-crosslinking speculation is possible but crosslinking with the accompanying proteins in vivo needs to be clarified in the text. A schematic illustration would be helpful.

Reviewer \#2: Abstract:

"...Advances have been achieved in many technologies, and one of the most developed methods is genetic code expansion with non-canonical amino acids (ncAAs) utilizing a pyrrolysyl-tRNA synthetase/ tRNA Pyl pair from Methanosarcina species;..."

What does most developed methods mean? This could just mean something with a reference system, otherwise it contains no information.

"... In the present study, we developed the new method to genetically incorporate ncAAs into N. meningitides..."

How can one introduce ncAAs into an organism? Maybe into a protein sequence?

"...In the present study, we developed the new method to genetically incorporate ncAAs into N. meningitidis and elucidate the biological function(s) of the NMB1345 protein in N. meningitidis by using ncAA-encoded photocrosslinking probes..."

Why extend the sentence unnecessarily? Say that your ncAAs are photcrosslinker. For example: In the present study, we developed the new method to genetically incorporate ncAA photocrosslinking probes into N. meningitidis and elucidate the biological function(s) of the NMB1345 protein in N. meningitidis

Introduction:

Line 42-45: "However, N. meningitidis exhibits the ability to cross the epithelial layer of the upper

43 respiratory tract, infiltrate the bloodstream, evade the defenses of the human immune

44 system, adhere to the endothelial layers of peripheral and brain vessels, cross the brain45

blood barrier, and replicate in cerebrospinal fluid."

Citation is missing.

Line 84-86: "We previously attempted using already existing methods, such as the two-hybrid system or a pull-down assay, to identify the proteins intarected with NMB1345 protein, but were unsuccessful."

Interacted is written wrong, also what does proteins interacted with NMB 1345 mean? Maybe protein-protein interaction?

Line 93: E. coli and C. elegans need to be written in full name. No full name before. Also C. elegans is written wrong.

Line 88-94: Needs rephrasing. The sentence is way to long. In addition, genetic code expansion with the Pyl system is anything but recently developed.

Line 97 99: No citation for the last claim in the sentence

Line 103-104: "\... most useful ..." this statement makes just sense if you say in what regard it is most useful. Nothing can be useful without stating the purpose.

Line 110: intection?

Line 111-112: If you state what PamA means, then do it the first time you use it, that would be in line 110.

Line 122: What are L plates or L broth? Please define or state the company.

Line 551: This sentence structure makes no sense. Your use of "and" implies that you genetically characterized the gene product. What does this mean? You did fluorescence.

Line 554: This is an interpretation of the data, normally in the text. In the figure caption one should describe what method was used and what was measured.

Line 563: using beneath makes no sense. Maybe you meant amongst or between strains?

Line 573-577: Sentence structure makes it almost incomprehensible.

Line 610-611: Your description is the opposite what the figure is showing, which is it?

Line 614: You say you used 123 amino acids but in figure 2B it is written that you used 113. Which is it? Figure 2B and the caption for that is confusing. Please clear up which parts you used and describe it with the correct length. Adapt the main text accordingly.

Line 616-618: This part is written extremely confusing. Where does strain 2215 and 2217 come from? Was not mentioned before or clearly described. Also Figure 2C does not annotate any of theses strains. Please adapt this.

Line 619-620: Please elaborate your conclusion.

Line 620-625: These claims are not evaluable since the Figure D and E are not consistent described. Please correct your Figure as mention above.

Line 630-632: "...while no one examined whether the orthogonality of the tRNAPyl-PylRS pair is specific or compatible with the meningococcal translational system."

This should be put into the introduction, not results.

Line 642: The general description for Fig. 3does not match what is shown. You don't show just the successful introduction of ncAAs into proteins.

Figure 3E: The gray arrow an text is not easy visible

Line 680: I guess you mean steric and not stereological. But since you have no further information why the suppression does not work I would omit this speculation. It could be also context effects, mRNA secondary structure effects, etc.

Line 684-685: "Moreover, when N. meningitidis was irradiated with UV light, a more dimer form of GST was detected with longer irradiation,..." Please rewrite, makes no sense

Line 705-707: What does this mean? Why mention HdeA from E.coli? Please elaborate the analogy or omit the sentence.

Line 709: "There were 40 Lys residues in the PamA protein\..." wrong tense. Doesn't PamA still has 40 Lys?

Line 720: You meant whole cell irradiation? Intact strains sounds weird.

Line 737: seemed not seemd

742-745: This sentence makes no sense, rewrite.

Line 747: The general description is not correct. Also boldening is not correct. Also no time of irradiation is mentioned.

Line 750: Portion?

Line 751: What was suppressed? How can an amino acid suppress something? Used several times. Please be more precise in the use of your language.

Line 759: If the contain other proteins then these are protein complexes.

Line 765-771: Super long sentence. Rephrase for clarity.

Line 789:-791 Why is there two times referred to A and one time to B. Just one time A.

Line 805-808: Phrasing makes no sense. Rephrase.

General remarks:

Check all abbreviations of consistency. Sometime you use IM for inner membrane; sometimes you use it for inner membrane-enriched fraction.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Hamid Reza Karbalaei-Heidari

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dr. Nediijko Budisa,

PLOS ONE

Academic editor

Dear Dr. Budisa,

Thank you very much for your favorable review of our manuscript.

We have revised our manuscript according to the comments of the academic editor and two reviewers. In addition, we carefully rewrote the entire manuscript to improve the English and asked a native speaker to correct the English.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

We revised the first page of manuscript to present on title, authors, affiliations, and corresponding author according to the PLOS ONE style.

2\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

We prepared the original image files according to these instructions. The original blots and gel images-files are as a PDF file in Supporting information, named as "Original blots and gel images".

3\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

We removed all of the descriptions mentioned as "data not shown".

Review Comments to the Author

Reviewer \#1: The manuscript has applied the genetic code expansion tools to reveal interaction of a hypothetical protein, NMB1345, to the PilE, a major component of meningococcal pili, in Neisseria meningiditis. Introduction of a new methodology to identify possible function of unknown factors in pathogenic bacteria is an interesting subject for further application of the orthogonal translation systems and create a new area of research. The manuscript has been prepared and written in scientific manner and just some minor issues has to be remained which mentioned below:

1- The quality of figures are very low and should be improved.

We revised all of the figures according to the PLOS ONE style, and hope the present quality of the figures is acceptable.

2- The number of figures is too high. Some of them could be moved in "Supporting information" part. For example, Fig. 4 and Fig. 7. Moreover, figures 5 and 6 should be combined.

Since we consider Fig 4B to be essential to comprehend the content of this study, we retained Fig 4B as Fig 4 and moved the previous Fig 4A to the supporting information as the new S3 Fig.

According to reviewer 1's suggestion, the previous Figures 5 and 6 were combined into one figure as the new Fig 5, and Fig 7 was moved to the supporting information as the new S7-9 Figs.

3- There is some mistyping in the text. For example: line 86, "intarected!!"; line 110, "intection!!"; line 149 in Table 1, readjusting needed; line 635, double typing or moving after ref.; line 737, "seemd!!"

The typographic errors in lines 86,110 and 737 were corrected.

Table 1 was arranged as follows: since Fig 4A was moved to the supporting information as S3 Fig, the description of the meningococcal plasmids in the supporting information (new S3 Fig) was moved to the new S4 Table.

Double typing at line 635 was corrected.

4- Line 122: "L plates"? Clarify.

We corrected the description "L broth" and "L plate" to Luria-Bertani (LB) broth and LB plate (LB liquid medium containing 1.5% agarose).

5- Line 803: "proteins"; only one protein highlighted in red, but in the text two proteins mentioned. Delete "s" or highlight the second one (NMEN93004-1215).

We deleted "s".

6- In Fig. 3B: Western blotting would not be able to confirm proper incorporation of ncAA. The MS analysis should be done. Please clarify this issue in corresponding part.

As reviewer 1 commented, from the physicochemical viewpoint, as MS analysis could confirm the proper incorporation of ncAA in OpaD K95amb, GST E51amb and GST F52amb.

On the other hand, purification of the OpaD and GST proteins from N. meningitidis strains was truly impossible since these proteins lacked tags and were expressed at comparable levels to endogenously produced proteins that could only be detected by Western blotting, as in higher organisms such as mammalian cells, Caenorhabditis elegans (ACS Chem Biol 20:1292-1302, 2012), neural cells (Stem cells 29:1231-1240, 2011) and zebrafish (Cell Research 27:294-297, 2017).

Considering of the technical difficulties, the purification of OpaD K95(mAzZLys) and OpaD K95(pBPa) from the N. meningitidis strain was impossible, and the results using OpaD K95amb shown in the former Fig 3BC were deleted in the revised manuscript.

As for GST E51(mAzZLys), GST E51(pBPa) and GST F52(pBPa), we constructed the new plasmids harboring gst genes fused to Strep2His6 tag for N. meningitidis. However, some materials required to introduce the plasmids into N. meningitidis were out of stock and we would have to wait for a month for their delivery. Moreover, even if we were able to obtain the N. meningitidis transformants, the purification of GST proteins followed by MS analysis will take approximately two months, since this is not an overproduction system. From these reasons, we could not purify GST E51(mAzZLys), GST E51(pBPa) and GST F52(pBPa) from N. meningitidis during this short period and could not prove the incorporation by MS analysis in the revised manuscript.

However, we purified the PamA K278(pBPa) protein from an N. meningitidis strain grown on approximately 200 plates (Fig 5A lane 6). We subjected the PamA K278(pBPa) protein to MS analysis and confirmed the selective incorporation of pBPa in N. meningitidis in the revised manuscript (S5 Fig).

We corrected the words "prove" or "confirm" to show that the proper incorporation of ncAA in GST E51amb and GST P52amb also occurred in N. meningitidis.

We hope our revised results sufficiently answer to the reviewer 1's comments.

7- The last but not least, please explain how chemically a protein like MBP-�N-PamA K278(pBPa) crosslinked to the endogenous proteins like Gln6-�N-PilE? Self-crosslinking speculation is possible but crosslinking with the accompanying proteins in vivo needs to be clarified in the text. A schematic illustration would be helpful.

In our experiments, both the MBP-�N-PamA K278(pBPa) and Gln6-�N-PilE proteins were overproduced and crosslinked in E. coli. Our poor explanation probably led to reviewer 1's confusion.

We revised the description to clearly show that the crosslinking between MBP-�N-PamA K278(pBPa) and Gln6-�N-PilE proteins was performed in E. coli. Moreover, a schematic illustration of these crosslinked proteins was added in S6D Fig.

We hope our revisions are suitable to answer for reviewer 1's comments.

Reviewer \#2:

Abstract:

"...Advances have been achieved in many technologies, and one of the most developed methods is genetic code expansion with non-canonical amino acids (ncAAs) utilizing a pyrrolysyl-tRNA synthetase/ tRNA Pyl pair from Methanosarcina species;..."

What does most developed methods mean? This could just mean something with a reference system, otherwise it contains no information.

We revised the sentence by adding the following phrase "Among many biological technologies to examine transient protein-protein interactions in vivo" (Lines 24-25).

"... In the present study, we developed the new method to genetically incorporate ncAAs into N. meningitides..."

How can one introduce ncAAs into an organism? Maybe into a protein sequence?

We revised the sentence by adding the following phrase: "encoded photocrosslinking probes into N. meningitidis by utilizing a pyrrolysyl-tRNA synthetase/tRNAPyl pair" (Lines 29-31).

"...In the present study, we developed the new method to genetically incorporate ncAAs into N. meningitidis and elucidate the biological function(s) of the NMB1345 protein in N. meningitidis by using ncAA-encoded photocrosslinking probes..."

Why extend the sentence unnecessarily? Say that your ncAAs are photcrosslinker. For example: In the present study, we developed the new method to genetically incorporate ncAA photocrosslinking probes into N. meningitidis and elucidate the biological function(s) of the NMB1345 protein in N. meningitidis

We revised the sentence according to reviewer's 2 suggestion as "we developed a new method to genetically incorporate ncAAs-encoded photocrosslinking probes into N. meningitidis by utilizing a pyrrolysyl-tRNA synthetase/tRNAPyl pair and elucidate the biological function(s) of the NMB1345 protein" (Lines 29-31).

Introduction:

Line 42-45: "However, N. meningitidis exhibits the ability to cross the epithelial layer of the upper

43 respiratory tract, infiltrate the bloodstream, evade the defenses of the human immune

44 system, adhere to the endothelial layers of peripheral and brain vessels, cross the brain45

blood barrier, and replicate in cerebrospinal fluid."

Citation is missing.

This citation was added in the revised manuscript (Line 44).

Line 84-86: "We previously attempted using already existing methods, such as the two-hybrid system or a pull-down assay, to identify the proteins intarected with NMB1345 protein, but were unsuccessful."

Interacted is written wrong, also what does proteins interacted with NMB 1345 mean? Maybe protein-protein interaction?

We revised the following phrase: "We previously attempted to examine protein-protein interaction using existing methods, such as the two-hybrid system and a pull-down assay, to find some cues on the function the NMB1345 protein" (Lines 82-85).

Line 93: E. coli and C. elegans need to be written in full name. No full name before. Also C. elegans is written wrong.

E. coli and C. elegans were rewritten as Escherichia coli and Caenorhabditis elegans, respectively (Lines 92-93).

Line 88-94: Needs rephrasing. The sentence is way to long. In addition, genetic code expansion with the Pyl system is anything but recently developed.

The sentence was divided into two parts. In addition, we removed the phrase "most recently" in the revised manuscript (Lines 87-94).

Line 97 99: No citation for the last claim in the sentence

The citation was added in the revised manuscript (Line 98).

Line 103-104: "\... most useful ..." this statement makes just sense if you say in what regard it is most useful. Nothing can be useful without stating the purpose.

We changed the phrase "most useful" to "most widely used" in the revised manuscript (Line 105).

Line 110: intection?

We corrected the mistyping.

Line 111-112: If you state what PamA means, then do it the first time you use it, that would be in line 110.

We mentioned the designation of NMB1345 as PamA in lines 109-110 in the revised manuscript.

Line 122: What are L plates or L broth? Please define or state the company.

Since both reviewers pointed out the same problems, we corrected the description "L broth" and "L plate" as Luria-Bertani (LB) broth and LB plate (LB liquid medium containing 1.5% agarose) (Lines 122-123).

Line 551: This sentence structure makes no sense. Your use of "and" implies that you genetically characterized the gene product. What does this mean? You did fluorescence.

We changed the title of Fig 1 to "Characterization of �pamA N. meningitidis" (Line 540).

Line 554: This is an interpretation of the data, normally in the text. In the figure caption one should describe what method was used and what was measured.

We changed the title of Fig 1B to "Effect of �pamA mutation on N. meningitidis infection of HBMEC" (Line 543).

Line 563: using beneath makes no sense. Maybe you meant amongst or between strains?

It is well known that bacterial infection elicits alternations of the signaling pathways concomitant with cytoskeletal reorganization in the host cells, and that ezrin is one of the key molecules controlling both cell shape and signaling. N. meningitidis reportedly induce ERM accumulation beneath the bacterial colony, and this accumulation is required for bacterial internalization into host cells (Takahashi et al, . IAI 2011, 2012 and 2015). This explanation was described in lines 560 to 562. In addition, since ezrin is the host cell's factor, we considered that "beneath" would be an appropriate word to show the part about the condensation of ezrin under the meningococcal colonies, and this word was often used in our previous manuscripts (Takahashi et al, IAI 2011, 2012 and 2015).

We hope the term "beneath" is acceptable for reviewer 2.

Line 573-577: Sentence structure makes it almost incomprehensible.

We revised the sentence for clarification (Lines 562-564).

Line 610-611: Your description is the opposite what the figure is showing, which is it?

As reviewer 2 pointed out, the description was opposite and corrected in the revised manuscript.

Line 614: You say you used 123 amino acids but in figure 2B it is written that you used 113. Which is it? Figure 2B and the caption for that is confusing. Please clear up which parts you used and describe it with the correct length. Adapt the main text accordingly.

We mistyped 23 as "123" in the previous version. PamA consists of the first 3 amino acids (aa) residues, the putative membrane-spanning region (20aa) and the hydrophilic region (493aa) as shown in Fig 2B. On the other hand, in the experiments with lacZ or phoA fusion, the first 136 aa were fused to the lacZ or phoA gene to genetically examine the orientation of PamA in N. meningitidis. We corrected the number.

Line 616-618: This part is written extremely confusing. Where does strain 2215 and 2217 come from? Was not mentioned before or clearly described. Also Figure 2C does not annotate any of these strains. Please adapt this.

The explanations of HT2215 and HT2217 are described in the text. To prevent confusion, the two strains are referred to in Table 2 and the strain names are also shown in Fig 2B.

Line 619-620: Please elaborate your conclusion.

Genetical methods are widely used to determine the orientation of a protein relative to the inner membrane in bacteria by expressing LacZ and PhoA fusion proteins, since the alkaline phosphatase activity of PhoA is active only in the periplasmic space (Boyle-Vavra et al, 1995). The explanation is added in Lines 608-609.

Line 620-625: These claims are not evaluable since the Figure D and E are not consistent described. Please correct your Figure as mention above.

As answered above, the descriptions of Fig 2 D and E were opposite in the text and corrected in the revised manuscript.

Line 630-632: "...while no one examined whether the orthogonality of the tRNAPyl-PylRS pair is specific or compatible with the meningococcal translational system."

This should be put into the introduction, not results.

The sentence "while no one examined whether the orthogonality of the tRNAPyl-PylRS pair is specific or compatible with the meningococcal translational system" was moved into the Introduction (Lines 98-100) in the revised manuscript.

Line 642: The general description for Fig. 3does not match what is shown. You don't show just the successful introduction of ncAAs into proteins.

Figure 3E: The gray arrow an text is not easy visible

As reviewer 2 pointed out, the title of Fig 3 was not suitable for the content. We corrected the tile as "Incorporation of ncAAs into N. meningitidis proteins monitored by Western blotting" (Line 630).

Line 680: I guess you mean steric and not stereological. But since you have no further information why the suppression does not work I would omit this speculation. It could be also context effects, mRNA secondary structure effects, etc.

As reviewer 2 pointed out, there are some reasons for the failure of mAzZLys incorporation at GST F52amb. However, we do not know the reason for the failure. To eliminate unnecessary confusion, the description of the steric hinderance was removed in the revised manuscript (Line 646).

Line 684-685: "Moreover, when N. meningitidis was irradiated with UV light, a more dimer form of GST was detected with longer irradiation,..." Please rewrite, makes no sense

We rewrote the sentence as "longer UV irradiation increased the amount of the dimer form of GST" (Line 658).

Line 705-707: What does this mean? Why mention HdeA from E.coli? Please elaborate the analogy or omit the sentence.

As reviewer 2 suggested the description of the E. coli HdeA protein was deleted in the revised manuscript.

Line 709: "There were 40 Lys residues in the PamA protein\..." wrong tense. Doesn't PamA still has 40 Lys?

As shown in S1 Fig, there are 40 Lys residues (shown in red) in the deduced amino acid sequence of the PamA protein.

Line 720: You meant whole cell irradiation? Intact strains sounds weird.

We rewrote the phrase "intact" as "whole bacterial cells" (Line 690).

Line 737: seemed not seemd

We corrected the mistyping.

742-745: This sentence makes no sense, rewrite.

We rewrote the sentence as "In the present study, we focused only on the proteins crosslinked to PamA K278(pBPa) because the three bands with the highest intensities were found in the PamA K278(pBPa) sample".

Line 747: The general description is not correct. Also boldening is not correct. Also no time of irradiation is mentioned.

Since we revised Fig 4 according to the reviewer 1's suggestion, the title for the new Fig 4 was rewritten in the revised manuscript.

This is the title of Fig 4, which is now shown in bold according to the guidelines.

PamA K208(pBPa), PamA K278(pBPa), PamA K314(pBPa), PamA K382(pBPa) and PamA K395(pBPa) proteins crosslinked to unidentified endogenous proteins in N. meningitidis. (Line 715-717)

While the irradiation time is described in the Materials and Methods, the irradiation time is also described in the figure citation (Line 720).

Line 750: Portion?

We rewrote the word as "aliquot" in the revised manuscript (Line 721)

Line 751: What was suppressed? How can an amino acid suppress something? Used several times. Please be more precise in the use of your language.

We meant to use the phrase "suppressed" in the genetic meaning. However, to exclude confusion, all phrases with "suppressed" in the old manuscript were rewritten as "expressed by pyrrolysine-based amber suppression with pBPa" in the revised manuscript.

Line 759: If the contain other proteins then these are protein complexes.

According to reviewer's 2 suggestion, we rewrote the phrase "proteins" as "protein complexes" (Line 726).

Line 765-771: Super long sentence. Rephrase for clarity.

Since the explanation of Twin-strep-tag was cited in the text (Korndorfer and Skerra, 2002), we shortened the sentence by deleting the explanation (Lines 727-728).

Line 789:-791 Why is there two times referred to A and one time to B. Just one time A.

According to reviewer 1's suggestion, we combined the previous Figs 4 and 5 into the new Fig 5. The revision changed the figure citations of the new Fig 5.

We corrected the reference to (A) in the figure citation of the new Fig 5.

Line 805-808: Phrasing makes no sense. Rephrase.

We rewrote the long sentences as follows: We then characterized the 85-kDa band, which could contain approximately 20 kDa endogenous protein crosslinked to PamA K278(pBPa). LC-MS/MS followed by MASCOT analyses revealed that two possible candidates, a fimbrial protein (17 kDa) and the hypothetical protein NMEN93004_1215 (18 kDa) (Table 3)(Lines 786-789).

General remarks:

Check all abbreviations of consistency. Sometime you use IM for inner membrane; sometimes you use it for inner membrane-enriched fraction.

We checked all of the abbreviations used in this study. As for the "IM", we intended IM to mean Inner membrane, but not the Inner-membrane-rich fraction, and corrected it for clarity.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

All figures were converted by PACE.

We appreciate your kind consideration of this revised manuscript and are looking forward to hearing a favorable response from you.

Sincerely yours,

Hideyuki Takahashi, Ph.D.

Department of Bacteriology I

National Institute of Infectious Diseases

Toyama 1-23-1, Shinjuku

Tokyo 162-8640, Japan

10.1371/journal.pone.0237883.r003
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If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Nediljko Budisa

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
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Reviewer \#2: (No Response)
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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